var title_f27_29_28112="TB of the spine Pott disease 2";
var content_f27_29_28112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberculosis of the spine (Pott disease)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 421px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI of 17-year-old fisherman showing tuberculous infection of adjacent thoracic vertebrae with intervening disc destruction and an anterior paraspinal abscess.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Malcolm McDonald, PhD, FRACP, FRCPA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28112=[""].join("\n");
var outline_f27_29_28112=null;
var title_f27_29_28113="Pseudoporphyria and vitiligo";
var content_f27_29_28113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pseudoporphyria in a patient with vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this patient with vitiligo, bullae developed in areas of pigment loss.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28113=[""].join("\n");
var outline_f27_29_28113=null;
var title_f27_29_28114="Patient information: Listeria (The Basics)";
var content_f27_29_28114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86716\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/39/33395\">",
"         Patient information: Avoiding infections in pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/1/31762\">",
"         Patient information: Bacterial meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/22/10595\">",
"         Patient information: Food poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/62/23521\">",
"         Patient information: Sepsis in newborn babies (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/29/36308\">",
"         Patient information: Acute diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Listeria (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H77112637\">",
"      <span class=\"h1\">",
"       What is Listeria?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Listeria is a type of bacteria that can cause fever, stomach upset, and other symptoms. People can get it from eating certain foods.",
"     </p>",
"     <p>",
"      Listeria can be mild or severe. It is not usually serious in healthy adults. But it can be more dangerous in pregnant women than in people who are not pregnant. Plus, a pregnant woman can pass Listeria to her unborn baby. The unborn baby can get very sick and even die.",
"     </p>",
"     <p>",
"      Certain other people are also at risk of getting very sick from Listeria. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Newborn babies",
"       </li>",
"       <li>",
"        Older people",
"       </li>",
"       <li>",
"        People who have AIDS, cancer, diabetes, or another serious medical condition",
"       </li>",
"       <li>",
"        People who had an organ transplant or stem cell transplant",
"       </li>",
"       <li>",
"        People who take medicines that make it hard for the body to fight off infections",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These people are more likely to get Listeria infections in the bloodstream or brain.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H77112652\">",
"      <span class=\"h1\">",
"       What are the symptoms of Listeria infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms are different depending on which part of the body is affected.",
"     </p>",
"     <p>",
"      People with Listeria infection in the",
"      <strong>",
"       brain and spinal cord",
"      </strong>",
"      can have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Stiff neck",
"       </li>",
"       <li>",
"        Confusion or trouble thinking",
"       </li>",
"       <li>",
"        Weak muscles on 1 side of the body, trouble walking, or shaky hands",
"       </li>",
"       <li>",
"        Seizures &ndash; Seizures are waves of abnormal electrical activity in the brain. They can make people pass out or move or behave strangely.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with Listeria infection in the",
"      <strong>",
"       bloodstream",
"      </strong>",
"      can have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Chills",
"       </li>",
"       <li>",
"        Dizziness",
"       </li>",
"       <li>",
"        Low blood pressure",
"       </li>",
"       <li>",
"        Fast heart rate",
"       </li>",
"       <li>",
"        Pain in joints and muscles",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with Listeria infection in the",
"      <strong>",
"       digestive system",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ) can have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Watery diarrhea",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Pain in joints and muscles",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H77112684\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call a doctor or nurse if you have any of the symptoms listed above and you are pregnant, older, have a serious medical condition, or take medicines that weaken the immune system.",
"     </p>",
"     <p>",
"      Call a doctor or nurse if your newborn baby:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Gets sick with a fever or any of the other symptoms listed above",
"       </li>",
"       <li>",
"        Acts differently from normal, such as feeding less than usual, breathing faster than usual, or looking sleepier than usual",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H77112699\">",
"      <span class=\"h1\">",
"       Is there a test for Listeria?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, there are a few different tests. Which ones you need will depend on your symptoms, whether you are pregnant, and if you have other medical conditions. Tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, a doctor puts a thin needle into your lower back and takes out a small amount of spinal fluid. Spinal fluid is the fluid around the brain and spinal cord. He or she will do tests on the fluid to look for Listeria.",
"       </li>",
"       <li>",
"        Tests on a sample of your bowel movement (if you could have Listeria that affects the digestive system)",
"       </li>",
"       <li>",
"        Imaging tests of the brain &ndash; These tests create pictures of the inside of the body. They can include an MRI or CT scan.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H77112714\">",
"      <span class=\"h1\">",
"       How is Listeria treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pregnant women, newborn babies, and people with serious Listeria infections are treated with medicines called antibiotics. These are usually given through a thin tube that goes into a vein called an &ldquo;IV.&rdquo; People who are very sick might need treatment in the hospital.",
"     </p>",
"     <p>",
"      Healthy adults with Listeria that affects the digestive system don&rsquo;t usually need treatment. The infection usually goes away on its own in about 2 days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H77112729\">",
"      <span class=\"h1\">",
"       Can Listeria be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting Listeria by paying attention to food safety. Tips include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Avoid unpasteurized milk and cheese or foods made with them",
"       </li>",
"       <li>",
"        Wash fruits and vegetables well before eating them",
"       </li>",
"       <li>",
"        Keep the refrigerator colder than 40&deg;F (4.4&deg;C) and the freezer below 0&deg;F (-18&deg;C)",
"       </li>",
"       <li>",
"        Cook meat and seafood until well done",
"       </li>",
"       <li>",
"        Cook eggs until the yolk is firm",
"       </li>",
"       <li>",
"        Wash hands, knives, and cutting boards after they touch raw food",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Pregnant women and people with weakened immune systems should avoid certain foods, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Raw milk",
"       </li>",
"       <li>",
"        Soft cheeses (including Mexican-style cheeses like queso blanco)",
"       </li>",
"       <li>",
"        Hot dogs",
"       </li>",
"       <li>",
"        Deli meats",
"       </li>",
"       <li>",
"        P&acirc;t&eacute;s",
"       </li>",
"       <li>",
"        Smoked seafood (such as lox)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also talk with your doctor or nurse about which foods to avoid.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H77112744\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=see_link\">",
"       Patient information: Avoiding infections in pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=see_link\">",
"       Patient information: Bacterial meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=see_link\">",
"       Patient information: Food poisoning (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/62/23521?source=see_link\">",
"       Patient information: Sepsis in newborn babies (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"       Patient information: Acute diarrhea in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/29/28114?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86716 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-2110654F66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28114=[""].join("\n");
var outline_f27_29_28114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77112637\">",
"      What is Listeria?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77112652\">",
"      What are the symptoms of Listeria infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77112684\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77112699\">",
"      Is there a test for Listeria?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77112714\">",
"      How is Listeria treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77112729\">",
"      Can Listeria be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77112744\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86716\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=related_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=related_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/62/23521?source=related_link\">",
"      Patient information: Sepsis in newborn babies (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_29_28115="Patient information: Polycystic ovary syndrome (The Basics)";
var content_f27_29_28115=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15605\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/4/36930\">",
"         Patient information: Absent or irregular periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/56/9090\">",
"         Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/16/11523\">",
"         Patient information: Infertility in women (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/22/9572\">",
"         Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/24/13698\">",
"         Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/46/30437\">",
"         Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33876\">",
"         Patient information: Weight loss treatments (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Polycystic ovary syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/polycystic-ovary-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H194800135\">",
"      <span class=\"h1\">",
"       What is polycystic ovary syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Polycystic ovary syndrome is a condition that can cause women to have irregular periods, get acne (oily skin and pimples), grow extra facial hair, or lose hair from their head. The condition can also make it hard to get pregnant. People sometimes refer to polycystic ovary syndrome as &ldquo;PCOS.&rdquo; It is very common &mdash; about 5 percent of all women have PCOS.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H194800142\">",
"      <span class=\"h1\">",
"       What causes PCOS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In women with PCOS, the ovaries don&rsquo;t work very well (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). About once a month, the ovaries are supposed to make a structure called a follicle. As the follicle grows, it makes hormones. Then, it releases an egg. This is called &ldquo;ovulation.&rdquo;",
"     </p>",
"     <p>",
"      But in women with PCOS, the ovary makes many small follicles instead of one big one. Hormone levels can get out of balance. And ovulation doesn&rsquo;t happen every month the way it is supposed to. Doctors aren&rsquo;t sure why this happens to some women.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H194800149\">",
"      <span class=\"h1\">",
"       What are the symptoms of PCOS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women with the condition might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have fewer than 8 periods a year",
"       </li>",
"       <li>",
"        Gain weight and become obese",
"       </li>",
"       <li>",
"        Grow thick, dark hair in places where only men tend to grow hair, such as on the upper lip, chin, sideburn area, chest, and belly",
"       </li>",
"       <li>",
"        Lose hair from their heads like men do",
"       </li>",
"       <li>",
"        Have acne (oily skin and pimples on their face)",
"       </li>",
"       <li>",
"        Have trouble getting pregnant",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H194800156\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse, even if my symptoms are mild?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Women with PCOS are more likely to end up with other health problems, too. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Diabetes (high blood sugar)",
"       </li>",
"       <li>",
"        High cholesterol levels",
"       </li>",
"       <li>",
"        Heart disease",
"       </li>",
"       <li>",
"        Sleep apnea, a sleep disorder that causes people to briefly stop breathing while they sleep",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H194800163\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests you should have based on your age, symptoms, and individual situation. Possible tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests to measure levels of hormones, blood sugar, and cholesterol",
"       </li>",
"       <li>",
"        A pregnancy test if you have missed any periods",
"       </li>",
"       <li>",
"        Pelvic ultrasound &ndash; This test uses sound waves to make a picture of your uterus and ovaries. Doctors use this test to check how many follicles are in your ovaries.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H194800170\">",
"      <span class=\"h1\">",
"       How is PCOS treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common treatment is to take birth control pills. The pills don&rsquo;t cure the disease. But they can improve many of its symptoms. Birth control pills also protect women from cancer of the uterus.",
"     </p>",
"     <p>",
"      Other treatments for symptoms of PCOS are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Anti-androgens &ndash; These medicines block hormones that cause some PCOS symptoms.",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/27/19893?source=see_link\">",
"         Spironolactone",
"        </a>",
"        (sold as Aldactone&reg;) is the antiandrogen that many doctors use.",
"       </li>",
"       <li>",
"        Progestin &ndash; This hormone can make you have regular periods, but only if you take it every month. It also lowers the risk of cancer. Most doctors use medroxyprogesterone (sold as Provera&reg;) or natural progesterone (sold as Prometrium&reg;).",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/358?source=see_link\">",
"         Metformin",
"        </a>",
"        (sold as Glucophage&reg;) &ndash; This medicine can help make a woman&rsquo;s periods more regular. But it works only in about one-half of women who try it. In women with diabetes, this medicine helps keep blood sugar levels normal.",
"       </li>",
"       <li>",
"        Medicated skin lotion or antibiotics to treat acne",
"       </li>",
"       <li>",
"        Laser therapy or electrolysis to remove extra hair",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H194800177\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to treat the condition?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you are overweight or obese, losing weight can improve many of your symptoms. Losing just 5 percent of your body weight can help a lot. That adds up to 10 pounds of weight loss for a 200-pound woman.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H194800184\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Don&rsquo;t lose hope. Most women with PCOS are able to get pregnant, but it can take a while. If you are overweight, losing weight can help make your periods regular and improve your chances of getting pregnant. If you lose weight but your periods are still irregular, your doctor can give you medicines that will help you ovulate and get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H194800191\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women with PCOS are able to live normal lives. But it is important to see a doctor. Treatments will help your symptoms and protect you from other diseases.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H194800198\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=see_link\">",
"       Patient information: Infertility in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=see_link\">",
"       Patient information: Absent or irregular periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/56/9090?source=see_link\">",
"       Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"       Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       Patient information: Weight loss treatments (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=see_link\">",
"       Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/29/28115?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15605 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28115=[""].join("\n");
var outline_f27_29_28115=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194800135\">",
"      What is polycystic ovary syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194800142\">",
"      What causes PCOS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194800149\">",
"      What are the symptoms of PCOS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194800156\">",
"      Should I see a doctor or nurse, even if my symptoms are mild?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194800163\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194800170\">",
"      How is PCOS treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194800177\">",
"      Is there anything I can do on my own to treat the condition?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194800184\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194800191\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194800198\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=related_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=related_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/56/9090?source=related_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=related_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_29_28116="Hemodynamics tamponade";
var content_f27_29_28116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemodynamics in cardiac tamponade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-mode through the minor axis in a patient with an anterior and posterior pericardial effusion and tamponade is seen in panel A; during inspiration, the right ventricle (RV) fills and the left ventricle (LV) becomes smaller; during expiration, the opposite occurs. In the graph in panel B, RV (RVEDd) and LV end diastolic diameters (LVEDd) are plotted against one another and demonstrate a negative correlation, a result of reciprocation of the chambers within the pericardium. Since the pericardium is a rigid box, as respiration brings more blood into the RV, there is less room in the LV; blood pools in the inflating lungs during inspiration. This blood plus the increased stroke volume sent to the lungs during RV inspiratory expansion reaches the lLV during expiration. As the LV expands, the RV is compressed. During RV expansion underfilling of the LV results in a drop in pulse pressure perceived as the paradoxical pulse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28116=[""].join("\n");
var outline_f27_29_28116=null;
var title_f27_29_28117="Lithium: Patient drug information";
var content_f27_29_28117=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lithium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     see \"Lithium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"     see \"Lithium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lithobid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lithium&reg; Carbonate;",
"     </li>",
"     <li>",
"      Apo-Lithium&reg; Carbonate SR;",
"     </li>",
"     <li>",
"      Carbolith&trade;;",
"     </li>",
"     <li>",
"      Duralith&reg;;",
"     </li>",
"     <li>",
"      Euro-Lithium;",
"     </li>",
"     <li>",
"      Lithane&trade;;",
"     </li>",
"     <li>",
"      Lithmax;",
"     </li>",
"     <li>",
"      PHL-Lithium Carbonate;",
"     </li>",
"     <li>",
"      PMS-Lithium Carbonate;",
"     </li>",
"     <li>",
"      PMS-Lithium Citrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You need to follow what the doctor told you about blood tests while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691371",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help low mood (depression) drugs work better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bold or forceful actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat manic low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat post-traumatic stress.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lithium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Fluid loss, very bad kidney disease, poor eating habits, or very bad heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697149",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor. Some of the drugs and diet used to treat a weak heart may change the lithium blood level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you start on a low-salt diet, tell your doctor. It will change the way your body handles the lithium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Passing urine often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much sweat or fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep your salt use the same from day to day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop tube feeding before giving this drug and restart after giving.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10813 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-2A6F391156-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28117=[""].join("\n");
var outline_f27_29_28117=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189343\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189344\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023302\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023304\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023303\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023308\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023309\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023311\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023306\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023307\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023312\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023313\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=related_link\">",
"      Lithium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=related_link\">",
"      Lithium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_29_28118="Forearm pronators supinators";
var content_f27_29_28118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Forearm pronators and supinators",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pronator quadratus and the pronator teres pronate the wrist. The pronator quadratus runs obliquely from the distal ulna to the more distal radius. The pronator teres originates from the medial epicondyle and the proximal ulna and inserts on the lateral midshaft of the radius. The supinators are much stronger than the pronators and include the supinator and the biceps brachii. The supinator originates on the proximal posterior ulna and inserts on the proximal radius. The biceps brachii has insertions on the radial tuberosity and the forearm flexor fascia through the bicipital aponeurosis or lacertus fibrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Jenkins, DB. Hollinhead's functional anatomy of the limbs and back, 6th edition, W.B. Saunders, Philadelphia 1991. Copyright &copy; 1991 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28118=[""].join("\n");
var outline_f27_29_28118=null;
var title_f27_29_28119="Treatment and prognosis of polyarteritis nodosa";
var content_f27_29_28119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of polyarteritis nodosa",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28119/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28119/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28119/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28119/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28119/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28119/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28119/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/29/28119/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries, with occasional involvement of small muscular arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients often present with systemic symptoms. Autopsies indicate the most common organ involved is the kidney, followed by the skin. As with other vasculitides, PAN, can affect any organ system, including the cardiovascular, gastrointestinal, and central nervous systems.",
"   </p>",
"   <p>",
"    The prognosis in untreated PAN is relatively poor, with one-year and five-year survival rates of approximately 50 and 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. The outcome has improved with therapy to approximately 80 percent survival at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and prognosis of polyarteritis nodosa will be reviewed here. The clinical manifestations, diagnosis, and classification of PAN are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SECONDARY PAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of severe necrotizing arteritis of medium sized arteries in association with a connective tissue disease (eg, systemic lupus erythematosus, rheumatoid arthritis, Sj&ouml;gren's syndrome), chronic viral infection (eg, hepatitis B or C), or hairy cell leukemia, is generally similar to that for idiopathic PAN. Interferon alfa may be beneficial in patients with PAN associated with hepatitis C or with hairy cell leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, interferon alfa may also be associated with exacerbation of the vasculitis and new cases of PAN have occurred during interferon alfa therapy for hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of these disorders is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22841?source=see_link\">",
"     \"Treatment of rheumatoid vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal disease associated with hepatitis B virus infection\", section on 'Polyarteritis nodosa'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal disease associated with hepatitis C virus infection\", section on 'Polyarteritis nodosa'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4378?source=see_link\">",
"     \"Treatment of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IDIOPATHIC PAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy of idiopathic PAN remains uncertain. However, plasmapheresis is not beneficial for the treatment of idiopathic PAN [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on observational studies, glucocorticoid therapy appears to be beneficial in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. Remission may be induced in approximately 50 percent of cases with glucocorticoids alone. The remaining 50 percent of patients require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in addition to glucocorticoids in order to achieve remission [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/1,10,11\">",
"     1,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    also appears to improve survival in patients with more severe disease when compared to steroid therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/3,4,10\">",
"     3,4,10",
"    </a>",
"    ]. Oral and intravenous cyclophosphamide appear to yield similar benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mild PAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because one-half of those with PAN remit with glucocorticoids alone, patients with relatively mild disease (such as that characterized by constitutional symptoms, arthralgia, anemia, normal renal function, and an absence of neurologic or gastrointestinal manifestations and those with isolated cutaneous disease) can be treated, at least initially, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone (or an equivalent glucocorticoid) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/12\">",
"     12",
"    </a>",
"    ]. Those who respond to this regimen may be spared the risk of adverse effects associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or other immunosuppressive drugs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initially,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is given at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum of 60 to 80 mg per day).",
"     </li>",
"     <li>",
"      In general, the initial high dose is continued for four weeks, until significant improvement is observed. The dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is then tapered slowly (eg, by 5 to 10 mg every 7 days), until a dose of 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is reached. The tapering schedule is then slowed (eg, to 1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every 7 days). This results in an overall course of approximately nine months. Some patients may require a slower taper, or continuation of prednisone to maintain disease control.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Isolated cutaneous PAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with isolated cutaneous disease who do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Mild PAN'",
"    </a>",
"    above),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    administration has been reportedly successful in controlling disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/13\">",
"     13",
"    </a>",
"    ]. Based on anecdotal experience, addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    to glucocorticoid therapy may be an alternative, provided the patient is not deficient in the enzyme thiopurine methyltransferase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacogenetics and TPMT testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Moderate and severe PAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been observed that those with more serious disease manifestations (ie, renal insufficiency, mesenteric artery ischemia, mononeuropathy multiplex) have better outcomes when treated with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids when compared to those who were treated with glucocorticoids alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/10\">",
"     10",
"    </a>",
"    ]. For those with moderately severe PAN who can tolerate oral therapy a commonly used regimen that we suggest is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , 1.5 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. In this setting, the white blood cell count (WBC) must be closely monitored and the cyclophosphamide dose adjusted to avoid severe leukopenia (WBC should remain above",
"      <span class=\"nowrap\">",
"       3500/mm3",
"      </span>",
"      and absolute neutrophil count above",
"      <span class=\"nowrap\">",
"       1500/mm3).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H24#H24\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      , given concurrently, at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum of 60 to 80 mg per day, or its equivalent)",
"     </li>",
"     <li>",
"      In general, the initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose is continued for approximately four weeks, until significant improvement is observed. The dose of prednisone is then tapered (eg, by 2.5 to 5 mg every 7 to 10 days), until a dose of 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is reached. The tapering schedule is then slowed (eg, to 1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every 7 days). This results in an overall course of approximately six months (shorter than with prednisone alone to avoid infectious complications given concurrent cytotoxic therapy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with severe, life-threatening manifestations or worsening mononeuropathy multiplex we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      each day for three days, be given initially to more rapidly control the inflammatory vasculitis, and then the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      regimen above is started [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients unable to tolerate oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy, those not likely to adhere to oral therapy, those who have a higher than average risk of bladder cancer, or those with more aggressive disease, intravenous cyclophosphamide can be used [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/15\">",
"       15",
"      </a>",
"      ]. The recommended dose is 600 to 750",
"      <span class=\"nowrap\">",
"       milligrams/m(2)",
"      </span>",
"      infused once a month for 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/14\">",
"       14",
"      </a>",
"      ]. A reduction in cyclophosphamide dose is necessary if there is significant renal insufficiency with not more than 500",
"      <span class=\"nowrap\">",
"       milligrams/m(2)",
"      </span>",
"      for those with end-stage or near end-stage renal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Novel and investigational therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports suggest that tumor necrosis factor inhibition may play a role in the treatment of some patients with polyarteritis nodosa [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, these therapies are not regarded as first-line treatments and should NOT be used in place of glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data available that address the optimal duration of therapy in patients with PAN. We recommend a minimum of six months and a maximum of 12 months of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . We suggest that patients who require cyclophosphamide because of glucocorticoid-resistant disease, can discontinue cyclophosphamide after disease control has been maintained for approximately six to nine months. In patients treated with cyclophosphamide for six to nine months we then treat for an additional six to nine months with another immunosuppressive agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/18\">",
"     18",
"    </a>",
"    ]. We suggest that patients with severe initial disease, if switched from cyclophosphamide to azathioprine, receive azathioprine in order to complete a total of up to 18 months of therapy. This approach is supported by evidence of efficacy in ANCA-associated systemic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most studies used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/4,8\">",
"     4,8",
"    </a>",
"    ], six months of cyclophosphamide may be sufficient for many patients, particularly those with mild disease. Prolonged (12 months) therapy with cyclophosphamide was associated with improved relapse free survival compared to six months of treatment (80 percent versus 55 percent) in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/20\">",
"     20",
"    </a>",
"    ]; however, this study combined the results for patients with PAN and microscopic polyangiitis.",
"   </p>",
"   <p>",
"    Because longer courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    are associated with higher risks of treatment-related morbidity, particularly, in older individuals who may have substantial comorbidity, cyclophosphamide is often discontinued after remission is induced followed by maintenance immunosuppressive therapy with a less toxic drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some investigators have found that relapses of active vasculitis are relatively uncommon in PAN among patients who enter a clinical remission [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/8,21\">",
"     8,21",
"    </a>",
"    ]. In a series of 260 patients, for example, fewer than 10 percent relapsed, but all patients requiring cytotoxic therapy were treated for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a major therapeutic issue in patients with polyarteritis nodosa. The elevation in blood pressure, may be severe, is often mediated by ischemia-induced activation of the renin-angiotensin system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/22\">",
"     22",
"    </a>",
"    ]. The intrarenal large vessel disease in polyarteritis nodosa may therefore be the functional equivalent of extrarenal vascular disease in bilateral renal artery stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=see_link\">",
"     \"Renal effects of ACE inhibitors in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Angiotensin converting enzyme (ACE) inhibitors are effective in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/23\">",
"     23",
"    </a>",
"    ]. However, they may worsen renal function due to removal of the effect of angiotensin II on autoregulation and maintenance of the glomerular filtration rate. Switching to other antihypertensive agents (such as calcium channel blockers) may be required if an ACE inhibitor induces a clinically significant elevation (&gt;20 or 30 percent) in the plasma creatinine concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment-related toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The required dose and duration of therapy with glucocorticoids and the use of combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    have the potential for serious treatment-related adverse effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      therapy (oral or intravenous) is associated with amenorrhea, infertility (in men and women), hemorrhagic cystitis, myelodysplasia, and in increase in the risk of malignancy including bladder cancer, lymphoma, and others [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High doses of corticosteroids predispose to oropharyngeal fungal infections, steroid-induced gastritis, bone loss and, particularly when used in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , to Pneumocystis jirovecii (carinii) pneumonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These potential complications and recommended prophylactic measures are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H12#H12\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of gonadal toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H16#H16\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of bladder toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the introduction, untreated PAN is associated with a poor prognosis (13 percent five-year survival) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Renal failure and mesenteric, cardiac, or cerebral infarction are the major causes of death. Some of these complications can occur at a time when the disease is clinically inactive, since healing of inflamed vessels can lead to progressive narrowing of the vascular lumina and resultant organ ischemia. As an example, a slowly progressive elevation in the serum creatinine concentration occurs in some patients in whom the signs of active vasculitis (such as systemic symptoms and an active urine sediment) have abated. The primary problem in this scenario is diminished glomerular flow, not vascular inflammation. Preservation of tissue function is most likely if treatment is instituted early in the course of the disease.",
"   </p>",
"   <p>",
"    The outcome has improved with therapy to approximately 80 percent survival at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the five-year survival of patients with hepatitis B-associated polyarteritis nodosa may be somewhat lower (73 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/24\">",
"     24",
"    </a>",
"    ]. Most deaths due to active disease (ie. failure to achieve remission) occur within the first 18 months of disease onset. Survival is better among those with limited organ involvement.",
"   </p>",
"   <p>",
"    Renal insufficiency (plasma creatinine &gt;1.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [140",
"    <span class=\"nowrap\">",
"     &micro;mol/L]),",
"    </span>",
"    gastrointestinal disease and central nervous system involvement are the most significant adverse prognostic indicators [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. Improvement in renal function may be seen even in patients who initially require dialysis. In this setting, sufficient recovery to allow the patient to be maintained off dialysis for one to two years or more occurs in up to 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/26\">",
"     26",
"    </a>",
"    ] and in approximately 10 percent who are dialyzed for as long as three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data exist concerning the outcome of patients with polyarteritis nodosa and end-stage renal disease who undergo renal transplantation. Among 112 patients with PAN reported in the ERA-EDTA registry, transplantation was associated with significantly lower patient (77 versus 91 percent) and first cadaveric allograft (60 versus 69 percent) survival rates compared with those diagnosed with a standard renal disease (eg, glomerulonephritis, interstitial nephritis, toxic nephropathies, and cystic kidney disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28119/abstract/28\">",
"     28",
"    </a>",
"    ]. Thirteen percent of graft failures were reportedly due to recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis of medium-sized muscular arteries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment improves five-year survival of PAN from &lt;20 percent to approximately 80 percent (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Prognosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mild PAN: Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with relatively mild disease (constitutional symptoms, arthritis, anemia, but normal renal function, no gastrointestinal involvement, and no neurologic deficits) and those with isolated cutaneous disease (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Mild PAN'",
"    </a>",
"    above) we recommend glucocorticoid monotherapy (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest an initial regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for approximately four weeks.",
"     </li>",
"     <li>",
"      Once significant improvement occurs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is tapered slowly for an overall course of approximately nine months.",
"     </li>",
"     <li>",
"      For patients with mild disease who do not respond to glucocorticoids alone, or who relapse as the dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is tapered, treatment is as described below for severe PAN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Moderate and severe PAN: Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who initially have more serious disease (eg, renal insufficiency, or gastrointestinal, cardiac or neurologic involvement), who are able to tolerate an oral regimen, we recommend initiating treatment with a combination of glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;(",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We suggest the following regimen (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Moderate and severe PAN'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, maximum of 60 to 80 mg per day) given concurrently. The initial high dose is continued for two to four weeks, until significant improvement is observed. The dose should then be tapered slowly, for an overall course of approximately six months.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , 1.5 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for up to one year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients unable to tolerate an oral regimen (eg, due to gastrointestinal involvement) and those patients with severe, life-threatening manifestations or worsening mononeuropathy multiplex, we suggest the following regimen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      be given initially for three days, followed by the oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      regimen.",
"     </li>",
"     <li>",
"      Monthly intravenous infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (initial dose 600 to 750",
"      <span class=\"nowrap\">",
"       milligrams/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per month), rather than oral administration in this setting for a total duration of up to one year. Dose adjustment is necessary for patients with end-stage or near end-stage renal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend a minimum of six months and a maximum of 12 months of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Duration of therapy'",
"    </a>",
"    above) (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). In patients treated with cyclophosphamide for six to nine months we treat for an additional six to nine months with another immunosuppressive agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    We suggest that patients who require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    because of glucocorticoid-resistant disease, can discontinue cyclophosphamide after disease control has been maintained for approximately six to nine months (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We suggest that patients with severe initial disease, if switched from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , receive azathioprine in order to complete a total of up to 18 months of therapy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adjunctive and prophylactic therapies: Recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend NOT using plasmapheresis (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Idiopathic PAN'",
"      </a>",
"      above) for the treatment of idiopathic PAN (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest treating hypertension with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor antagonists, with appropriate monitoring for side effects (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=see_link\">",
"       \"Renal effects of ACE inhibitors in hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"       \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend providing prophylactic therapy for glucocorticoid induced bone loss (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , we recommend prophylactic therapy against Pneumocystis jirovecii (carinii) pneumonia with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients receiving intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , we suggest concurrent administration of mercaptoethane sulfonate (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       MESNA",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H16#H16\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of bladder toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women of reproductive age who desire to reduce the risk of ovarian failure we suggest administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H12#H12\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of gonadal toxicity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/1\">",
"      Balow JE. Renal vasculitis. Kidney Int 1985; 27:954.",
"     </a>",
"    </li>",
"    <li>",
"     Conn, DL. Polyarteritis. In: Rheumatology, Klippel, JH, Dieppe, PA (Eds), Mosby, St Louis, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/3\">",
"      Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med 1967; 43:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/4\">",
"      Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/5\">",
"      Beuthien W, Mellinghoff HU, Kempis Jv. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005; 24:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/6\">",
"      Carpenter MT, West SG. Polyarteritis nodosa in hairy cell leukemia: treatment with interferon-alpha. J Rheumatol 1994; 21:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/7\">",
"      Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004; 24:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/8\">",
"      Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/9\">",
"      Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/10\">",
"      Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/11\">",
"      Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/12\">",
"      Ribi C, Cohen P, Pagnoux C, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 2010; 62:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/13\">",
"      Schartz NE, Alaoui S, Vignon-Pennamen MD, et al. Successful treatment in two cases of steroid-dependent cutaneous polyarteritis nodosa with low-dose methotrexate. Dermatology 2001; 203:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/14\">",
"      Guillevin L, Pagnoux C. When should immunosuppressants be prescribed to treat systemic vasculitides? Intern Med 2003; 42:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/15\">",
"      Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/16\">",
"      Al-Bishri J, le Riche N, Pope JE. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 2005; 32:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/17\">",
"      Keystone EC. The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis 2004; 63 Suppl 2:ii79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/18\">",
"      Stone JH. Polyarteritis nodosa. JAMA 2002; 288:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/19\">",
"      Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/20\">",
"      Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003; 49:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/21\">",
"      Guillevin L. Treatment of classic polyarteritis nodosa in 1999. Nephrol Dial Transplant 1999; 14:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/22\">",
"      Stockigt JR, Topliss DJ, Hewett MJ. High-renin hypertension in necrotizing vasculitis. N Engl J Med 1979; 300:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/23\">",
"      Cohen L, Guillevin L, Meyrier A, et al. [Malignant arterial hypertension in periarteritis nodosa. Incidence, clinicobiologic parameters and prognosis based on a series of 165 cases]. Arch Mal Coeur Vaiss 1986; 79:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/24\">",
"      Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/25\">",
"      Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/26\">",
"      Hind CR, Paraskevakou H, Lockwood CM, et al. Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet 1983; 1:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/27\">",
"      Nissenson AR, Port FK. Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders. Q J Med 1990; 74:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28119/abstract/28\">",
"      Briggs JD, Jones E. Renal transplantation for uncommon diseases. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. Nephrol Dial Transplant 1999; 14:570.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8244 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28119=[""].join("\n");
var outline_f27_29_28119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SECONDARY PAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IDIOPATHIC PAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mild PAN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Isolated cutaneous PAN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Moderate and severe PAN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Novel and investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment-related toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mild PAN: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Moderate and severe PAN: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adjunctive and prophylactic therapies: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4378?source=related_link\">",
"      Treatment of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22841?source=related_link\">",
"      Treatment of rheumatoid vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_29_28120="Diagnostic imaging procedures during pregnancy";
var content_f27_29_28120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic imaging procedures during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28120/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28120/contributors\">",
"     Jonathan B Kruskal, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28120/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28120/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28120/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28120/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/29/28120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preconceptional ovarian exposure to diagnostic levels of ionizing radiation has no measurable effect on future pregnancies. Therefore, the ideal time to schedule radiologic procedures in women of reproductive age is during the first 10 days of the menstrual cycle, if possible. At the time of the radiologic examination, all women of childbearing potential should be asked if they could be pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/1\">",
"     1",
"    </a>",
"    ]. If any doubt exists, the results of a pregnancy test should be obtained before proceeding.",
"   </p>",
"   <p>",
"    Sometimes diagnostic imaging is necessary during pregnancy, and utilization rates appear to be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/2\">",
"     2",
"    </a>",
"    ]. Sonographic examination of the uterus and its contents is a common occurrence in pregnant women, but other types of radiological evaluation may also be required. Although the safety of radiation exposure during pregnancy is a common concern, a missed or delayed diagnosis can pose a greater risk to the woman and her pregnancy than any hazard associated with ionizing radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/3\">",
"     3",
"    </a>",
"    ]. In many cases, the perception of fetal risk is higher than the actual risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. For the woman herself, the effects of ionizing radiation are the same whether or not she is pregnant, and will not be dealt with in this topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15365103\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple national and international organizations have written guidelines on imaging the pregnant patient. A comprehensive resource including the names of 17 of these organizations and their 33 reports was published in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/6\">",
"     6",
"    </a>",
"    ]. The following discussion includes information derived from several of these reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RADIATION BASICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any discussion of the effects of radiation requires background knowledge of radiation nomenclature and dosimetry. The absorbed dose of radiation is the amount of energy deposited per kilogram of tissue and is measured in \"rads.\" One rad is the energy transfer of 100 ergs per gram of any absorbing material. The following relationships apply to diagnostic X-rays in soft tissue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1 rad = 0.01 gray (Gy) = 0.01 sievert (Sv) = 1 rem (roentgen-equivalent man)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, the average person is exposed to an effective radiation dose equivalent of approximately 3.1 mSv (310 mrem) whole-body exposure per year from natural sources [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/7\">",
"     7",
"    </a>",
"    ]. The US Nuclear Regulatory Commission (10 CFR 20) recommends that occupational radiation exposure of pregnant women not exceed 5 mSv (500 mrem) to the",
"    <span class=\"nowrap\">",
"     embryo/fetus",
"    </span>",
"    during the entire pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=see_link&amp;anchor=H6#H6\">",
"     \"Biology and clinical features of radiation injury in adults\", section on 'Examples of possible radiation exposures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTS OF IONIZING RADIATION ON THE FETUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies in humans from which to derive data on risks of ionizing radiation; most of our information is based upon case reports and extrapolation of data from investigations of survivors of the atomic bomb in Japan and the Chernobyl accident [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/9-15\">",
"     9-15",
"    </a>",
"    ]. Based on these data, the potential deleterious consequences of ionizing radiation can be divided into four categories [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pregnancy loss (miscarriage, stillbirth)",
"     </li>",
"     <li>",
"      Malformation",
"     </li>",
"     <li>",
"      Disturbances of growth or development",
"     </li>",
"     <li>",
"      Mutagenic and carcinogenic effects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The occurrence of each effect depends upon the gestational age at the time of radiation exposure, the dose of radiation absorbed by the fetus, and fetal cellular repair mechanisms. Cellular damage caused by low levels of radiation exposure is usually repaired by a number of physiologic processes. In contrast, high level exposure can interrupt important events in cell development and maturation, which may cause permanent injury or death.",
"   </p>",
"   <p>",
"    The effects of radiation can be considered as either deterministic (exposure affects severity of outcome) or stochastic (exposure affects probability of outcome). The deterministic effects are dose-related and occur when many cells are affected by radiation; a large number of affected cells results in more significant clinical problems. If injury to these cells occurs during a critical stage of organogenesis (primarily but not exclusively days 15 to 50 after conception), impairment, agenesis, or deformity of the developing organ can occur (",
"    <a class=\"graphic graphic_figure graphicRef56642 \" href=\"UTD.htm?22/46/23272\">",
"     figure 1",
"    </a>",
"    ). As an example, microcephaly develops if a large number of differentiating central nervous system cells are injured.",
"   </p>",
"   <p>",
"    Stochastic effects are monoclonal, resulting in changes to the cell genome and altered differentiation and function of the affected cells. The probability, but not the severity, of the effect increases with the radiation dose. As an example, the increased risk of thyroid cancer as a result of in utero exposure to radiation after the Chernobyl accident is a stochastic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Exposure less than 0.05 Gy (5 rads)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic imaging procedures typically expose the fetus to this level of radiation (",
"    <a class=\"graphic graphic_table graphicRef75594 \" href=\"UTD.htm?23/2/23596\">",
"     table 1",
"    </a>",
"    ). There is NO evidence of an increased risk of fetal anomalies, intellectual disability, growth restriction, or pregnancy loss from ionizing radiation at doses less than 0.05 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The margin of safety is augmented by the fact that most human exposures from diagnostic imaging will be fractionated over a period of time; this type of exposure is less harmful than acute exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Carcinogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal data suggest that carcinogenic effects are most pronounced during late fetal development [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/19\">",
"     19",
"    </a>",
"    ]. Low levels (eg, 0.01 to 0.02 Gy [1 to 2 rad]) of in utero radiation exposure may increase the risk of childhood cancer, particularly leukemia, by a factor of 1.5 to 2 over the baseline incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]. However, the carcinogenic potential of low level radiation is controversial since nonirradiated siblings of these children also have a higher incidence of leukemia. Furthermore, children exposed in utero at the bombing of Hiroshima and Nagasaki have not developed a significantly increased rate of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An estimate of the risk of childhood leukemia in various populations is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef67090 \" href=\"UTD.htm?41/39/42619\">",
"     table 2",
"    </a>",
"    ). Although an increased risk of radiation-induced carcinogenesis in children exposed in utero cannot be excluded, the general consensus is that this risk is not likely to exceed 1 in 1000 children per rad of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Solid cancer incidence rates have been examined among survivors of the atomic bombings of Hiroshima and Nagasaki who were in utero (n = 2452) or younger than 6 years (n = 15388) at the time of the bombings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/23\">",
"     23",
"    </a>",
"    ]. Both the in utero and early childhood groups exhibited statistically significant dose-related increases in incidence rates of solid cancers, but the lifetime risks following in utero exposure were much lower than for early childhood exposure. At age 50, the estimated excess absolute rate per 10,000 person-years per Gy was 6.8 (95% CI &lt;0 to 49) for those exposed in utero and 56 (95% CI 36 to 79) for those exposed as young children. There was NO increase in oncogenic risk for exposures less than 0.2 Gy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Exposure 0.05 to 0.50 Gy (5 to 50 rads)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The threshold at which an increased risk of congenital malformations is observed in radiation exposed",
"    <span class=\"nowrap\">",
"     embryos/fetuses",
"    </span>",
"    has not been definitively determined. The evidence suggests the risk of malformations is increased at doses above 0.10 Gy, whereas the risk between 0.05 and 0.10 Gy is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/24\">",
"     24",
"    </a>",
"    ]. It is important to note that even those diagnostic imaging procedures associated with high fetal radiation exposure (eg, abdominal or pelvic CT,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema, cystourethrogram) almost never expose the fetus to this level of radiation (",
"    <a class=\"graphic graphic_table graphicRef75594 \" href=\"UTD.htm?23/2/23596\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     First 14 days after conception",
"    </span>",
"    &nbsp;&mdash;&nbsp;The developing human is most sensitive to the lethal effects of ionizing radiation during the first 14 days after conception. During this period, the radiation-exposed \"embryo\" either survives undamaged or is resorbed (termed the \"all or none\" phenomenon) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/25\">",
"     25",
"    </a>",
"    ]. Radiation-induced teratogenesis, growth restriction, or carcinogenesis are NOT observed during this stage of development [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/18\">",
"     18",
"    </a>",
"    ], presumably because of the pluripotent nature of each cell of the very early embryo.",
"   </p>",
"   <p>",
"    For human exposure, a conservative estimate of the threshold for death at this stage is more than 0.1 Gy rads (10 rads) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/19\">",
"     19",
"    </a>",
"    ]. A fetal dose of 1 Gy (100 rads) will likely kill 50 percent of embryos; the dose necessary to kill 100 percent of human embryos or fetuses before 18 weeks of gestation is about 5 Gy (500 rads).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     After the first 14 days",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the period of organogenesis (approximately 2 to 8 weeks after fertilization or 4 to 10 weeks after the last menstrual period), the embryo may be damaged as a result of radiation-induced cell death, disturbances in cell migration and proliferation, or mitotic delay [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/26\">",
"     26",
"    </a>",
"    ]. Lethality is rare.",
"   </p>",
"   <p>",
"    The major sequelae of radiation damage at this stage are fetal growth restriction and congenital malformations, particularly of the central nervous system (eg, microcephaly, intellectual disability, gross eye abnormalities). Microcephaly is the most frequently cited manifestation of radiation injury in utero [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/27\">",
"     27",
"    </a>",
"    ]. In the absence of any of these findings, the presence of other types of malformations in humans should not be attributed to radiation exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After approximately 20 to 25 weeks of gestation, the fetus is relatively resistant to teratogenic effects of ionizing radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malformations &mdash; For the developing fetus under 16 weeks of gestation, the threshold for possible prenatal radiation effects is approximately 0.10 to 0.20 Gy (10 to 20 rads) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/19\">",
"       19",
"      </a>",
"      ]. After 16 weeks of gestation, the consensus of most researchers is that this threshold is much higher, at least 0.50 to 0.70 Gy (50 to 70 rads).",
"     </li>",
"     <li>",
"      Mental retardation &mdash; Studies in survivors of the Hiroshima atomic bomb demonstrated that the risk of mental retardation and microcephaly was highest for radiation exposures at 8 to 15 weeks after conception [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/10\">",
"       10",
"      </a>",
"      ]. The abnormalities were attributed to alterations in neuronal development. No cases of severe intellectual disability were identified in the children of atomic bomb survivors who were exposed prior to 8 weeks or after 25 weeks following conception. The risk appeared to be a linear function of dose, with a threshold of 0.12 Gy (12 rads) at 8 to 15 weeks, and 0.21 Gy (21 rads) at 16 to 25 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/11-14\">",
"       11-14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In addition, at 8 to 15 weeks, the average IQ loss was approximately 25 to 31 points per Gy (per 100 rads) above 0.1 Gy (10 rads), and the risk for severe intellectual disability was approximately 40 percent per Gy (per 100 rads) above 0.1 Gy (10 rads). By comparison, at 16 to 25 weeks, the average IQ loss was approximately 13 to 21 points per Gy at doses above 0.7 Gy, and the risk of severe intellectual disability was approximately 9 percent per Gy above 0.7 Gy.",
"     </li>",
"     <li>",
"      Growth restriction &mdash; Atomic bomb survivor data showed a permanent restriction of physical growth with increasing radiation dose, particularly above 1 Gy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/19\">",
"       19",
"      </a>",
"      ]. This was most pronounced when the exposure occurred in the first trimester. A 3 to 4 percent reduction in height at age 18 occurred when the dose was greater than 1 Gy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation may increase the frequency of naturally occurring mutations; it does not induce mutations unique to this source. Small increases in the rate of genomic mutation are difficult to detect because the background rate of spontaneous mutation is already high (about 10 percent), recessive mutations take several generations to become apparent, and autosomal dominant mutations are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/12\">",
"     12",
"    </a>",
"    ]. There is currently no way to distinguish radiation-induced genetic mutations from similar conditions arising from other environmental exposures. Studies attempting to estimate the incidence of radiation mutagenesis have been based largely upon animal and plant experiments. Very few human data are available, apart from observations in the offspring of Japanese atomic bomb survivors. An increased risk of genetic disorders induced by ionizing radiation has not been demonstrated in any human population at any radiation dose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/12,29\">",
"     12,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FETAL EXPOSURE FROM COMMON PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no known significant fetal effects from exposure to diagnostic ultrasound or magnetic resonance imaging involving a magnetic field at 1.5 Tesla or lower. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Ultrasound'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H26\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The estimated fetal exposures for some common imaging procedures involving ionizing radiation are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef75594 \" href=\"UTD.htm?23/2/23596\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/26,30,31\">",
"     26,30,31",
"    </a>",
"    ]. Although several such tables are available, dosimetry calculations vary widely.",
"   </p>",
"   <p>",
"    When counseling a pregnant woman about the radiation risks associated with a diagnostic procedure, the estimated dose for the specific patient should be calculated by a radiologist familiar with dosimetry. Factors to be considered include the number and type of projections, exposure time, distance, x-ray output, and use of digital acquisition systems designed to limit dosage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ISSUES BY TYPE OF DIAGNOSTIC IMAGING PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic imaging during pregnancy can involve ionizing radiation (eg, plain x-rays, fluoroscopy and angiography, computed tomography [CT], nuclear medicine) or nonionizing techniques (eg, ultrasound, magnetic resonance [MR] imaging). In addition, various contrast agents may be administered to enhance diagnostic sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Procedures using ionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic x-rays of the head, neck, chest, and limbs produce almost no scatter to the embryo; any radiation received would not result in a measurably increased risk. Nevertheless, the patient should wear a lead apron to minimize fetal exposure from radiation scatter whenever non-abdominopelvic sites are being imaged. A fast",
"    <span class=\"nowrap\">",
"     film/screen",
"    </span>",
"    combination or digital radiography can also be used to reduce total radiation exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Plain films",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques can be used to minimize fetal radiation exposure during abdominopelvic x-ray procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A posterior-anterior (PA) exposure lowers the radiation dose by 0.02 to 0.04 mGy (2 to 4 mrad) compared with the traditional anterior-posterior (AP) exposure because the uterus is located in an anterior pelvic position,",
"     </li>",
"     <li>",
"      Shutters can be employed to collimate the radiation beam and reduce scatter.",
"     </li>",
"     <li>",
"      Avoiding both magnification near the uterus and use of grids results in a decreased dose of radiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Fluoroscopy and angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;During fluoroscopic and angiographic procedures, modifying the exposure time, number of films obtained, beam size, and imaging area can reduce the amount of radiation exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intravenous pyelography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal and pelvic ultrasound are recommended as the initial diagnostic imaging study when an obstructing calculus is suspected. Ultrasound is useful for detecting secondary signs of obstruction, such as hydronephrosis or hydroureter, while avoiding exposure to ionizing radiation. Endovaginal ultrasound is more sensitive than transabdominal ultrasound for detecting distal ureteral calculi [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link&amp;anchor=H4#H4\">",
"     \"Renal and urinary tract physiology in normal pregnancy\", section on 'Ureters'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If after ultrasound examination it is still considered necessary to obtain an intravenous pyelogram (IVP), the radiation dose can be minimized by obtaining a single abdominal radiograph approximately five minutes after intravenous administration of contrast material [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/33\">",
"     33",
"    </a>",
"    ]. This will provide information about the relative excretory function of each kidney, and will demonstrate the site and extent of obstruction of a ureter. The single-shot IVP delivers about 0.5 mGy (50 mrad) to the fetus, a value that is equal to federal guideline for the maximum radiation exposure recommended for pregnant women over a one-month interval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal radiation dose from a CT scan is affected by several variables, including the number, location, and thickness of slices. When CT imaging is performed in pregnancy, using a narrow collimation and wide pitch (ie, the patient moves through the scanner at a faster rate) results in a slightly reduced image quality, but provides a large reduction in radiation exposure. Scanning protocols should also be modified. As an example, if performing a CT scan with contrast, the number of acquisitions can be reduced by eliminating the precontrast series. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=see_link\">",
"     \"Principles of computed tomography of the chest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal radiation exposure during nonabdominal CT scans is minimal. As an example, the radiation exposure from maternal head CT is approximately 2 mGy (200 mrad) for the mother and less than 0.10 mGY (10 mrad) for the fetus if the abdomen is shielded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Dental x rays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiation dose to the fetus from maternal dental radiography is minute, 0.0001 mGy (0.01 mrads) for an average study, and is not considered harmful. Although one population based case-control study found an association between antepartum dental radiography of &gt;0.4 mGy (40 mrads) to the maternal thyroid and low birthweight (less than 2500 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/34\">",
"     34",
"    </a>",
"    ], this association is not consistent with findings from multiple other studies and is not biologically plausible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/17\">",
"     17",
"    </a>",
"    ]. Further investigation is needed before any change is made to the recommendations for dental imaging in pregnant women. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammography during pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H23#H23\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'Pregnancy and lactation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Iodinated contrast materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodinated contrast materials cross the placenta and can produce transient effects on the developing fetal thyroid gland, although clinical sequelae from brief exposures have not been reported. Iodinated contrast materials may be used in pregnancy, when indicated.",
"   </p>",
"   <p>",
"    The use of contrast agents in breastfeeding women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H23#H23\">",
"     \"Principles of medication use during lactation\", section on 'Intravenous contrast agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nuclear medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuclear medicine studies (eg, pulmonary ventilation-perfusion, thyroid, bone, and renal scans) use a radioisotope bound to a chemical agent. The effect of these substances on the fetus depends upon placental permeability, fetal distribution, tissue affinity, and the half-life, dose, and type of radiation emitted. Substances that can localize in specific fetal organs and tissues, and thus may be of concern, include iodine-131 or iodine-123 in the thyroid, iron-59 in the liver, gallium-67 in the spleen, and strontium-90 and yttrium-90 in the skeleton. Fetal exposure also results from proximity to radionuclides excreted into the maternal bladder; maternal hydration and frequent voiding can reduce this type of exposure.",
"   </p>",
"   <p>",
"    Some radionuclides will appear in breast milk. After administration of radionuclides, breast feeding should be suspended for the period of time that radioactivity is present; this will depend upon the half-life of the specific agent. Breast milk can be pumped and discarded until nursing is resumed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H24#H24\">",
"     \"Principles of medication use during lactation\", section on 'Radiopharmaceuticals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnant women may have contact with individuals who have received radioactive materials as part of a diagnostic study; the minimal residual radioactivity does not result in a measurably increased risk to the embryo. Radiation exposure from close contact is higher after some types of therapeutic radiation (eg, radioiodine therapy of thyroid cancer, brachytherapy implants for prostate cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. A period of restricted contact may be prudent, depending upon the type of therapy and degree of exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Ventilation-perfusion and helical CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A ventilation-perfusion (V-P) scan for suspected pulmonary embolus is among the most common nuclear medicine studies obtained in pregnant women. The procedure involves perfusion with Tc 99m macroaggregates of albumin and ventilation with radiolabeled xenon gas or 99m Tc DTPA aerosol. Helical CT is another commonly used test for diagnosis of suspected pulmonary embolus and is also associated with a low radiation dose to the fetus. One study estimated that in the third trimester, fetal radiation exposure from chest radiography, helical CT, V-P scanning, and pulmonary arteriography (with a brachial approach) was 0.01, 0.13, 0.37, and 0.50 mGy, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/37\">",
"     37",
"    </a>",
"    ]. The mean radiation dose was lower earlier in gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Thyroid scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the 10th to 12th week of gestation, radioiodine isotopes are readily absorbed by the fetal thyroid. Although there are no reports of adverse fetal effects from diagnostic doses of radioactive iodine, it should NOT be administered to pregnant women because induction of thyroid cancer in the offspring is a concern [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/26\">",
"     26",
"    </a>",
"    ]. If a diagnostic scan of the thyroid is required, the preferred agents are Technetium Tc 99m or I-123 (but not I-131) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/20,38\">",
"     20,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Positron emission tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is minimal information regarding positron emission tomography (PET) in pregnancy. This technique involves injection of a radioisotope, fludeoxyglucose F 18. Animal reproduction studies have not been conducted with fludeoxyglucose F 18 Injection and it is not known whether fludeoxyglucose F 18 Injection can cause fetal harm when administered to a pregnant woman, or can affect reproduction capacity. The radiation dose to the uterus is 3.70 to 7.40 mGy, for the usual dose range of isotope injected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/39\">",
"     39",
"    </a>",
"    ]. As discussed above, this is a low fetal dose and not associated with adverse effects on development or growth.",
"   </p>",
"   <p>",
"    Because of the lack of safety data in human pregnancy, MR imaging or CT are generally preferred to PET as they usually provide similar information, but the decision needs to be made on a patient specific basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;No biologic effects have been documented from diagnostic ultrasound in the pregnant patient, despite intensive use over several decades. The potential for deleterious consequences from heat and cavitation exists since ultrasound uses sound waves that interact with biological tissues. B-mode and M-mode imaging operate at acoustic outputs that do not produce harmful temperature rises. However, Doppler ultrasound does have this potential; therefore, guidelines for Doppler use in pregnancy have been formulated. The use of ultrasound in pregnancy is discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36824?source=see_link\">",
"       \"Ultrasound examination in obstetrics and gynecology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27592?source=see_link\">",
"       \"Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"       \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=see_link\">",
"       \"Venous Doppler for fetal assessment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A limitation of ultrasound is that it does not show soft tissue detail as well as magnetic resonance imaging or computed tomography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance (MR) imaging uses electromagnetic radio waves, rather than ionizing radiation, to generate detailed computer images. At the cellular level, possible direct biologic effects of MR imaging consist of (1) induction of local electric fields and currents from the static and time varying magnetic fields, and (2) radiofrequency radiation resulting in heating of tissue. Other potential dangers include trauma from projection of metal objects into the magnetic field (eg, small metal fragments can be projected into the eyes), interference with the operation of electronic devices (eg, cardiac pacemakers) or position of metallic implants, burns from heating of conductive materials in implants, and acoustic damage from high intensity noise.",
"   </p>",
"   <p>",
"    Despite these concerns, there are NO reported harmful effects from MR imaging of the pregnant woman or fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. However, safety studies have been performed predominantly at or below 1.5 Tesla magnetic field strengths. There may be an increased risk of tissue heating at higher field strengths. In some cases, MR imaging is the preferred diagnostic modality because it provides better images than ultrasonography, while avoiding the ionizing radiation of computed tomography. Although the National Radiological Protection Board advises that MR imaging be",
"    <strong>",
"     avoided in the first trimester",
"    </strong>",
"    since there is limited experience assessing safety during organogenesis, MR imaging should be considered in the first trimester when the benefit exceeds the theoretic risk. As an example, first trimester MR imaging is a reasonable option in a pregnant women with suspected appendicitis in whom the appendix cannot be visualized by ultrasound examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26949515\">",
"    <span class=\"h3\">",
"     Gadolinium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gadolinium, the contrast agent most commonly used for MR imaging because of its magnetic properties, crosses the placenta and is excreted by the fetus into the amniotic fluid. It is then swallowed so it can be reabsorbed into the fetal circulation. Given the potentially long half-life in the fetus and few data from human pregnancy, it is not recommended for use in the pregnant patient unless the potential benefit justifies the potential risk to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/20,43\">",
"     20,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When use of gadolinium is essential, available data are reassuring. Although limited to descriptions of individual cases and small case series, adverse fetal or pregnancy effects from gadolinium exposure have not been reported in human pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Animal studies have not shown adverse effects from clinically-based doses and a murine study found that fetal levels were undetectable 48 hours after maternal administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/48\">",
"     48",
"    </a>",
"    ]. Doses 2.5 to 12.5 times usual human doses (usual dose: 0.1",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    to 0.2",
"    <span class=\"nowrap\">",
"     mmol/kg)",
"    </span>",
"    given daily for 10 to 13 days have resulted in slight retardation of development in rats and rabbits. In one study of rabbits that received doses of 0.3, 0.9 or 2.0",
"    <span class=\"nowrap\">",
"     mmol/kg/day,",
"    </span>",
"    morphological examination of fetuses exposed to 2.0",
"    <span class=\"nowrap\">",
"     mmol/kg/day",
"    </span>",
"    revealed small",
"    <span class=\"nowrap\">",
"     eye/microphthalmia",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retinal irregularities and vertebral abnormalities in some fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28120/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ideally, semi-elective radiologic procedures are scheduled during the first 10 days (follicular phase) of the menstrual cycle. All women of childbearing potential should be asked if they could be pregnant at the time of a radiologic examination. If any doubt exists, a pregnancy test should be obtained prior to the diagnostic procedure. The perceived risk of radiation exposure is much greater than the actual risk, but a full explanation of these risks to the woman and her family is best given prior to, rather than after, the exposure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During pregnancy, ultrasound examination and magnetic resonance imaging are generally preferred to imaging modalities that involve ionizing radiation. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Ultrasound'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, concern about the possible effects of ionizing radiation should not prevent medically indicated diagnostic procedures using the best available modality for the clinical situation. When procedures requiring ionizing radiation are necessary, various techniques can be employed to minimize the radiation dose. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Effects of ionizing radiation on the fetus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Issues by type of diagnostic imaging procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiation risks should be discussed with the pregnant patient, including an explanation of the background population risk for miscarriage, congenital anomalies, genetic disease, and growth restriction (approximately 20, 4, 10, and 10 percent, respectively), as well as the risk of developmental disorders. Consultation with a radiologist should be obtained to plan the optimum study using the least amount of radiation or to reconstruct the amount of radiation exposure from examinations performed prior to knowledge of the pregnancy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Effects of ionizing radiation on the fetus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Fetal exposure from common procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At doses less than 0.05 Gy, there is no evidence of an increased risk of fetal anomalies, intellectual disability, growth restriction, or pregnancy loss from ionizing radiation. There may be a small increased risk of childhood cancer, 1 in 2000 versus the 1 in 3000 background rate. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Exposure less than 0.05 Gy (5 rads)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the first 14 days after fertilization, intact survival or death are the most likely outcomes of radiation exposure above 0.05 Gy (5 rads). A conservative estimate of the threshold for intrauterine death is more than 0.1 Gy (10 rads). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'First 14 days after conception'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the first 14 days, radiation exposure over 0.5 Gy may be associated with an increased risk of congenital malformations, growth restriction, and intellectual disability. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'After the first 14 days'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gadolinium is currently NOT recommended for use in the pregnant patient. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Iodinated contrast materials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are no reports of adverse fetal effects from diagnostic doses of radioactive iodine, it should NOT be administered to pregnant women because induction of thyroid cancer in the offspring is a concern. If a diagnostic scan of the thyroid is required, the preferred agents are Technetium Tc 99m or I-123 (but not I-131). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Thyroid scan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The National Radiological Protection Board advises that magnetic resonance imaging be avoided in the first trimester since there is limited experience assessing safety during organogenesis. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/1\">",
"      Applegate K. Pregnancy screening of adolescents and women before radiologic testing: does radiology need a national guideline? J Am Coll Radiol 2007; 4:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/2\">",
"      Lazarus E, Debenedectis C, North D, et al. Utilization of imaging in pregnant patients: 10-year review of 5270 examinations in 3285 patients--1997-2006. Radiology 2009; 251:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/3\">",
"      McCollough CH, Schueler BA, Atwell TD, et al. Radiation exposure and pregnancy: when should we be concerned? Radiographics 2007; 27:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/4\">",
"      Ratnapalan S, Bona N, Chandra K, Koren G. Physicians' perceptions of teratogenic risk associated with radiography and CT during early pregnancy. AJR Am J Roentgenol 2004; 182:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/5\">",
"      Bentur Y, Horlatsch N, Koren G. Exposure to ionizing radiation during pregnancy: perception of teratogenic risk and outcome. Teratology 1991; 43:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/6\">",
"      Austin LM, Frush DP. Compendium of national guidelines for imaging the pregnant patient. AJR Am J Roentgenol 2011; 197:W737.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nrc.gov/reading-rm/doc-collections/fact-sheets/bio-effects-radiation.html (Accessed on September 04, 2012).",
"    </li>",
"    <li>",
"     file://www.gpo.gov/fdsys/pkg/CFR-2011-title10-vol1/xml/CFR-2011-title10-vol1-part20.xml (Accessed on September 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/9\">",
"      Castronovo FP Jr. Teratogen update: radiation and Chernobyl. Teratology 1999; 60:100.",
"     </a>",
"    </li>",
"    <li>",
"     United Nations Scientific Committee on the Effects of Atomic Radiation, Sources and Effects of Ionizing Radiation, UN Publication E.94.IX.2, UN Publications, United Nations, New York, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/11\">",
"      Hall EJ. Scientific view of low-level radiation risks. Radiographics 1991; 11:509.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Biological Effects of Ionizing Radiation, Board on Radiation Effects Research Commission on Life Sciences, National research Council. Health effects of exposure to low levels of ionizing radiation: BEIR V. Washington, DC, 1990. p. 352.",
"    </li>",
"    <li>",
"     Schull, WJ, Otake, M. Neurological deficit among the survivors exposed to the atomic bombing of Hiroshima and Nagasaki: A reassessment and new directions. In: Radiation risks to the developing nervous system, Schmahl, W, Gerber, GB, Stive, FE (Eds), Gustave Fischer Verlag, New York 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/14\">",
"      Otake M, Schull WJ, Yoshimaru H. A review of forty-five years study of Hiroshima and Nagasaki atomic bomb survivors. Brain damage among the prenatally exposed. J Radiat Res 1991; 32 Suppl:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/15\">",
"      Wertelecki W. Malformations in a chornobyl-impacted region. Pediatrics 2010; 125:e836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/16\">",
"      Yamazaki JN, Schull WJ. Perinatal loss and neurological abnormalities among children of the atomic bomb. Nagasaki and Hiroshima revisited, 1949 to 1989. JAMA 1990; 264:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/17\">",
"      Brent RL. Saving lives and changing family histories: appropriate counseling of pregnant women and men and women of reproductive age, concerning the risk of diagnostic radiation exposures during and before pregnancy. Am J Obstet Gynecol 2009; 200:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/18\">",
"      Brent RL. The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. Semin Oncol 1989; 16:347.",
"     </a>",
"    </li>",
"    <li>",
"     www.bt.cdc.gov/radiation/prenatalphysician.asp (Accessed on July 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/20\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol 2004; 104:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/21\">",
"      Stewart A, Kneale GW. Radiation dose effects in relation to obstetric x-rays and childhood cancers. Lancet 1970; 1:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/22\">",
"      Kato H. Mortality in children exposed to the A-bombs while in utero, 1945-1969. Am J Epidemiol 1971; 93:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/23\">",
"      Preston DL, Cullings H, Suyama A, et al. Solid cancer incidence in atomic bomb survivors exposed in utero or as young children. J Natl Cancer Inst 2008; 100:428.",
"     </a>",
"    </li>",
"    <li>",
"     www.icrp-84.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/25\">",
"      De Santis M, Cesari E, Nobili E, et al. Radiation effects on development. Birth Defects Res C Embryo Today 2007; 81:177.",
"     </a>",
"    </li>",
"    <li>",
"     Bentur, Y. Ionizing and nonionizing radiation in pregnancy. In: Maternal-fetal toxicology, 2nd ed, Koren, G (Ed), Marcel Dekker, New York 1994.",
"    </li>",
"    <li>",
"     Mettler, FA, Upton, AC. Medical Effects of Ionizing Radiation, 2nd ed, WB Saunders, Philadelphia, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/28\">",
"      De Santis M, Di Gianantonio E, Straface G, et al. Ionizing radiations in pregnancy and teratogenesis: a review of literature. Reprod Toxicol 2005; 20:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/29\">",
"      Ritenour ER. Health effects of low level radiation: carcinogenesis, teratogenesis, and mutagenesis. Semin Nucl Med 1986; 16:106.",
"     </a>",
"    </li>",
"    <li>",
"     Kereiakes, JG, Rosenstein, M. Handbook of Radiation Doses in Nuclear Medicine and Diagnostic X-ray, CRC Press, Boca Raton 1980.",
"    </li>",
"    <li>",
"     United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources and Effects of ionizing radiation. Report to the General Assembly, 1977. p. 319.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/32\">",
"      Laing FC, Benson CB, DiSalvo DN, et al. Distal ureteral calculi: detection with vaginal US. Radiology 1994; 192:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/33\">",
"      Butler EL, Cox SM, Eberts EG, Cunningham FG. Symptomatic nephrolithiasis complicating pregnancy. Obstet Gynecol 2000; 96:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/34\">",
"      Hujoel PP, Bollen AM, Noonan CJ, del Aguila MA. Antepartum dental radiography and infant low birth weight. JAMA 2004; 291:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/35\">",
"      Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. JAMA 2000; 283:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/36\">",
"      Cattani F, Vavassori A, Polo A, et al. Radiation exposure after permanent prostate brachytherapy. Radiother Oncol 2006; 79:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/37\">",
"      Winer-Muram HT, Boone JM, Brown HL, et al. Pulmonary embolism in pregnant patients: fetal radiation dose with helical CT. Radiology 2002; 224:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/38\">",
"      Ginsberg JS, Hirsh J, Rainbow AJ, Coates G. Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost 1989; 61:189.",
"     </a>",
"    </li>",
"    <li>",
"     www.easternisotopes.com/products/package_insert.html. (Accessed November 10, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/40\">",
"      Duncan KR. The development of magnetic resonance imaging in obstetrics. Br J Hosp Med 1996; 55:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/41\">",
"      Kirkinen P, Partanen K, Vainio P, Ryyn&auml;nen M. MRI in obstetrics: a supplementary method for ultrasonography. Ann Med 1996; 28:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/42\">",
"      Nicklas AH, Baker ME. Imaging strategies in the pregnant cancer patient. Semin Oncol 2000; 27:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/43\">",
"      Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007; 188:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/44\">",
"      De Santis M, Straface G, Cavaliere AF, et al. Gadolinium periconceptional exposure: pregnancy and neonatal outcome. Acta Obstet Gynecol Scand 2007; 86:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/45\">",
"      Barkhof F, Heijboer RJ, Algra PR. Inadvertent i.v. administration of gadopentetate dimeglumine during early pregnancy. AJR Am J Roentgenol 1992; 158:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/46\">",
"      Shoenut JP, Semelka RC, Silverman R, et al. MRI in the diagnosis of Crohn's disease in two pregnant women. J Clin Gastroenterol 1993; 17:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/47\">",
"      Marcos HB, Semelka RC, Worawattanakul S. Normal placenta: gadolinium-enhanced dynamic MR imaging. Radiology 1997; 205:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/48\">",
"      M&uuml;hler MR, Cl&eacute;ment O, Salomon LJ, et al. Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in mice. Radiology 2011; 258:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28120/abstract/49\">",
"      Okuda Y, Sagami F, Tirone P, et al. [Reproductive and developmental toxicity study of gadobenate dimeglumine formulation (E7155) (3)--Study of embryo-fetal toxicity in rabbits by intravenous administration]. J Toxicol Sci 1999; 24 Suppl 1:79.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4791 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28120=[""].join("\n");
var outline_f27_29_28120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15365103\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RADIATION BASICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTS OF IONIZING RADIATION ON THE FETUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Exposure less than 0.05 Gy (5 rads)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Carcinogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Exposure 0.05 to 0.50 Gy (5 to 50 rads)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - First 14 days after conception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - After the first 14 days",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FETAL EXPOSURE FROM COMMON PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ISSUES BY TYPE OF DIAGNOSTIC IMAGING PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Procedures using ionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Plain films",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Fluoroscopy and angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intravenous pyelography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Dental x rays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Mammography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Iodinated contrast materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nuclear medicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Ventilation-perfusion and helical CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Thyroid scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Positron emission tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26949515\">",
"      - Gadolinium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4791\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4791|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/46/23272\" title=\"figure 1\">",
"      The developing fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4791|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/2/23596\" title=\"table 1\">",
"      Fetal radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/39/42619\" title=\"table 2\">",
"      In utero radiation leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27592?source=related_link\">",
"      Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=related_link\">",
"      Biology and clinical features of radiation injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=related_link\">",
"      Principles of computed tomography of the chest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36824?source=related_link\">",
"      Ultrasound examination in obstetrics and gynecology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=related_link\">",
"      Venous Doppler for fetal assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_29_28121="Adenocarcinoma of unknown primary site";
var content_f27_29_28121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adenocarcinoma of unknown primary site",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28121/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28121/contributors\">",
"     John D Hainsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28121/contributors\">",
"     F Anthony Greco, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28121/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28121/contributors\">",
"     George P Canellos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28121/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/29/28121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of unknown primary site (CUP) is a relatively common clinical entity, accounting for 4 to 5 percent of all invasive cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/1\">",
"     1",
"    </a>",
"    ]. Within this category, tumors from many primary sites with varying biology are represented. This heterogeneity has made the design and interpretation of clinical studies difficult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=see_link\">",
"     \"Overview of the classification and management of cancers of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenocarcinomas of unknown primary site comprise approximately 70 percent of CUPs. In these patients, the focus is on identifying specific subsets in which disease-oriented therapy may be more effective than empiric therapy; this is based upon a combination of clinical features, immunohistochemistry (IHC), and molecular tumor profiling.",
"   </p>",
"   <p>",
"    The diagnosis and management of patients with adenocarcinoma of unknown primary are reviewed here. The diagnosis and management of the other CUPs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=see_link\">",
"     \"Overview of the classification and management of cancers of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of adenocarcinoma of unknown primary site increases with age. The clinical presentation is determined by the sites of metastatic tumor involvement, which are frequently multiple and often include the liver, lungs, lymph nodes, and bones.",
"   </p>",
"   <p>",
"    In autopsy series, the most frequently identified primary sites are lung, pancreas, hepatobiliary tree, and kidney, together accounting for approximately two-thirds of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/2\">",
"     2",
"    </a>",
"    ]. However, tumors may arise from a wide variety of other primary sites. Adenocarcinomas of the breast and prostate are identified infrequently at autopsy, despite being the most common cancers in women and men, respectively. In 20 to 30 percent of patients, no primary site can be identified.",
"   </p>",
"   <p>",
"    Large autopsy series include patients who were not evaluated with modern imaging techniques such as computerized tomography (CT) and positron emission tomography (PET). Thus the published data may not accurately reflect the current patient population with adenocarcinoma of unknown primary.",
"   </p>",
"   <p>",
"    Many patients with adenocarcinoma of unknown primary have widespread metastases and poor performance status at diagnosis (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ). The outlook for most of these patients is poor, with a median survival of four to six months in older reports (",
"    <a class=\"graphic graphic_table graphicRef82737 \" href=\"UTD.htm?11/34/11821\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, small subsets of patients have a more favorable outlook, and initial evaluation should attempt to identify these patients. In addition, empiric chemotherapy incorporating newer agents has produced higher response rates and probably improved survival in patients with good performance status (see",
"    <a class=\"local\" href=\"#H315626628\">",
"     'Treatment for patients not included in specific subgroups'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of adenocarcinoma is usually based upon the identification of glandular structures that are formed by the neoplastic cells. These features are shared by all adenocarcinomas, and the site of the primary tumor usually cannot be determined by light microscopy. Although certain morphologic features can be associated with a particular tumor type (eg, papillary features with ovarian cancer and signet ring cells with gastric cancer), they generally are not sufficiently specific to provide a definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Poorly differentiated adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of poorly differentiated adenocarcinoma is usually made when only minimal glandular formation is seen on histologic examination or in tumors that lack glandular differentiation but stain positively for mucin. Adenocarcinoma, poorly differentiated adenocarcinoma, and poorly differentiated carcinoma are histologic diagnoses that represent a spectrum of tumor differentiation rather than well-demarcated entities. Different pathologists may use somewhat different criteria for each of these diagnoses.",
"   </p>",
"   <p>",
"    The light microscopic diagnosis of poorly differentiated adenocarcinoma should be interpreted with caution, since some of these patients have a distinctive tumor biology and responsiveness to systemic chemotherapy. For this reason, evaluation and treatment of patients with poorly differentiated adenocarcinoma of unknown primary should follow the guidelines outlined for poorly differentiated carcinoma of unknown primary, including the use of immunohistochemical staining and electron microscopy to identify potentially chemotherapy-responsive cancer and rule out other tumor types such as hematologic malignancies, sarcomas, or germ cell tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a few cases, immunohistochemistry (IHC) may provide strong evidence regarding the primary site for some adenocarcinomas (",
"    <a class=\"graphic graphic_table graphicRef62750 \" href=\"UTD.htm?23/26/23980\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56518 \" href=\"UTD.htm?29/14/29932\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, positive staining for prostate-specific antigen (PSA) is quite specific for prostate cancer and should be included in the evaluation of men with adenocarcinoma of unknown primary site. Similarly, the detection of thyroglobulin by IHC is relatively specific for thyroid cancer.",
"   </p>",
"   <p>",
"    In most cases, however, IHC is not specific enough for definitive identification of the site of origin, but may suggest the most likely primary site (",
"    <a class=\"graphic graphic_figure graphicRef54258 \" href=\"UTD.htm?29/49/30482\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56518 \" href=\"UTD.htm?29/14/29932\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, IHC staining for the estrogen (ER) or progesterone receptor (PR) suggests metastatic breast cancer in women with adenocarcinoma of unknown primary. However, other primary sites (ovary, endometrium, nonreproductive organs) may also express these markers. Another example is thyroid transcription factor-1 (TTF-1), which is a marker for both lung adenocarcinomas and small cell carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other patients with adenocarcinoma of unknown primary, batteries of IHC stains have been used to suggest the most likely primary site (",
"    <a class=\"graphic graphic_figure graphicRef54258 \" href=\"UTD.htm?29/49/30482\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56518 \" href=\"UTD.htm?29/14/29932\">",
"     table 4",
"    </a>",
"    ). These panels have included cytokeratins (CK) 20 and 7, gross cystic disease fluid protein 15, breast cancer antigen (BCA) 225, carcinoembryonic antigen (CEA), vimentin, CA 19-9, and CA-125 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Although suggestive, these stains may not be specific enough to dictate treatment.",
"   </p>",
"   <p>",
"    The pattern of results with CK20 and CK7 may be particularly helpful in suggesting a primary site (",
"    <a class=\"graphic graphic_table graphicRef62750 \" href=\"UTD.htm?23/26/23980\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58475 \" href=\"UTD.htm?20/45/21212\">",
"     table 5",
"    </a>",
"    ). CK20 is a low molecular weight cytokeratin that is normally expressed in the gastrointestinal epithelium, urothelium, and in Merkel cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/12\">",
"     12",
"    </a>",
"    ]. CK7 is expressed by tumors of the lung, ovary, endometrium, and breast, but not in tumors of the lower gastrointestinal tract.",
"   </p>",
"   <p>",
"    Thus, the phenotype",
"    <span class=\"nowrap\">",
"     CK20+/CK7-",
"    </span>",
"    supports the diagnosis of a colorectal carcinoma. This was illustrated in a study of 93 autopsy cases of adenocarcinoma of known primary site involving the liver, in which a",
"    <span class=\"nowrap\">",
"     CK20+/CK7-",
"    </span>",
"    pattern correctly predicted a colorectal primary in 17 of 21 cases (81 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/11\">",
"     11",
"    </a>",
"    ]. In the same study, a",
"    <span class=\"nowrap\">",
"     CK20+/CK7+",
"    </span>",
"    pattern predicted a cancer of pancreatic or biliary origin in 11 of 14 cases (79 percent). The",
"    <span class=\"nowrap\">",
"     CK20-/CK7+",
"    </span>",
"    group was too heterogeneous to be classified adequately by these two antibodies.",
"   </p>",
"   <p>",
"    None of these IHC results has been prospectively evaluated for accuracy in identifying the primary site in patients with carcinoma of unknown primary site. Likewise, no studies have addressed the question of whether treatment based upon these IHC \"diagnoses\" improves the outcome for these patients. Thus, the results of IHC staining should be interpreted in conjunction with the clinical presentation and histologic findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Molecular tumor profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific gene expression profiles are observed in cancers from different sites of origin, reflecting the different gene expression profiles of the normal tissues of origin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/12\">",
"     12",
"    </a>",
"    ]. Molecular tumor profiling enables prediction of a tissue of tumor origin based on detection of site-specific gene expression profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several molecular assays are commercially available, using either RT-PCR or gene microarray techniques, which have not been directly compared with each other [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Turnaround time to obtain results is one to two weeks. However, confirmation of the accuracy of molecular tumor profiling in predicting the tissue of origin in patients with CUP is difficult, since the anatomic primary site rarely becomes manifest in these patients.",
"   </p>",
"   <p>",
"    When tested in a blinded fashion, these assays accurately identified the tissue of origin in approximately 85 percent of patients with advanced cancers of known primary site. In retrospective studies, molecular profiling has yielded a prediction of the probable primary tumor site in most CUP patients, and most predictions have been consistent with the clinical and pathologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. As an example, in a group of 20 CUP patients who later had the primary site identified clinically, the molecular profiling predictions were &ldquo;correct&rdquo; in 15 (75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of molecular profiling predictions on therapeutic results in patients with CUP is not fully established. However, developing data suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subgroups of CUP patients with treatable tumors (eg, colorectal, breast, ovary) can be reliably identified by molecular tumor profiling, and can benefit from site-specific therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The overall survival of an unselected group of CUP patients is improved with site-specific therapy based on molecular profiling predictions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, molecular tumor profiling should be included in the diagnostic evaluation of patients with CUP when clinical and standard pathologic evaluations are not strongly suggestive of a primary site.",
"   </p>",
"   <p>",
"    Additional prospective studies are necessary to define the role of molecular tumor profiling more precisely, and to define the differences, if any, among the currently available assays. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INITIAL CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive clinical identification of the tumor's site of origin is unusual in a patient presenting with adenocarcinoma of unknown primary site [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/22\">",
"     22",
"    </a>",
"    ]. Initial studies focus on determining the extent of metastatic disease, as well as identifying those patients whose tumors were likely to have arisen in a treatable primary site.",
"   </p>",
"   <p>",
"    At a minimum, this initial evaluation should include a thorough history and physical examination, complete blood count, urinalysis, basic serum chemistries, and computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis. In men, assessment should incorporate a prostate examination and measurement of serum prostate specific antigen (PSA). In women, the evaluation should include a pelvic examination and mammography. Breast MRI should be performed in the setting of a negative mammogram in women with adenocarcinoma involving the axillary lymph nodes (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Women with axillary lymph node metastases'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Positron emission tomography (PET) is currently a standard diagnostic staging procedure in a large number of cancer types. In a number of retrospective series, PET identified a primary site in approximately 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Although prospective series in which patients have standardized diagnostic evaluations prior to PET are still needed, the current evidence supports inclusion of PET scanning in the routine evaluation of CUP.",
"   </p>",
"   <p>",
"    Exhaustive imaging and endoscopic testing should not be performed, since these studies rarely detect the primary site in the asymptomatic patient and confusion can result from false-positive results. Instead, the presence of specific signs or symptoms should guide the choice of additional studies. Colonoscopy should be performed in patients with intraabdominal metastases who have a",
"    <span class=\"nowrap\">",
"     CK20+/CK7-",
"    </span>",
"    IHC staining pattern, a positive CDX-2 IHC stain, or a molecular tumor profile predictive of colorectal cancer. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Immunohistochemistry'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Molecular tumor profiling'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Commonly measured serum tumor markers (CEA, CA 19-9, CA 15-3, CA 125) are generally not useful as diagnostic or prognostic tests. However, they are commonly elevated and may be useful in following the response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SPECIFIC PATIENT SUBGROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The group of patients with adenocarcinoma of unknown primary site contains several clinically defined subgroups for which specific therapy is available. All patients who fit into one of these subgroups after the clinical and pathologic evaluations have been completed should receive specific therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Women with peritoneal carcinomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women, adenocarcinoma causing diffuse peritoneal involvement without an obvious primary tumor usually originates in the ovary or in extraovarian tissues with similar histogenesis. Disease-directed therapy can result in a relatively favorable outlook in these patients compared to adenocarcinoma of unknown primary site of nonovarian origin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pathology and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, these tumors arise from the peritoneal surface, which shares a common histogenesis with ovarian tissues. Many have morphologic features that are typical for epithelial ovarian carcinoma, such as papillary configuration or psammoma bodies. In such cases, this syndrome has been termed serous carcinoma of the peritoneum (SCP) or multifocal extraovarian serous carcinoma.",
"   </p>",
"   <p>",
"    Some patients may present with a poorly differentiated adenocarcinoma that does not exhibit a papillary configuration (analogous to poorly differentiated epithelial ovarian carcinomas); they should be approached similarly to those with typical serous histology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link&amp;anchor=H5#H5\">",
"     \"Epithelial ovarian cancer: Pathology\", section on 'Epithelial carcinomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumors arising within the mesothelial cells may share a common biology with ovarian carcinoma, a concept that is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritoneal carcinomatosis occurs more commonly in women with BRCA1 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/27\">",
"       27",
"      </a>",
"      ] and occasionally in women from families at high risk for ovarian cancer who have undergone prophylactic oophorectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"       \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"       \"Screening for ovarian cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical features are often typical of advanced ovarian cancer, with tumor involvement limited to the peritoneal surfaces and elevated serum concentrations of CA 125. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"       \"Screening for ovarian cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with PSCP may include a multimodality approach that includes surgical debulking and systemic chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical cytoreduction should be considered in patients with bulky disease. In patients with epithelial ovarian cancer, debulking may provide the best chance for long-term remission, although the optimal timing is controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H7#H7\">",
"       \"Epithelial ovarian cancer: Initial surgical management\", section on 'Cytoreduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with PSCP often respond well to chemotherapy regimens that are effective in the treatment of advanced epithelial ovarian cancer. Several studies have documented high initial response rates similar to those seen in patients with advanced ovarian carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/30-34\">",
"       30-34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Women with axillary lymph node metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer should be suspected in women (and rarely, in men) who have an adenocarcinoma of unknown primary site and axillary lymphadenopathy. Multiple series have demonstrated that women presenting with axillary lymphadenopathy have a much better prognosis than those with adenocarcinoma of other unknown primary sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link&amp;anchor=H4#H4\">",
"     \"Axillary node metastases with occult primary breast cancer\", section on 'Initial diagnostic workup'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link&amp;anchor=H17#H17\">",
"     \"Axillary node metastases with occult primary breast cancer\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To support a diagnosis of breast cancer, immunohistochemical (IHC) staining for estrogen receptor, progesterone receptor, HER2 expression, and other breast cancer-specific markers such as mammaglobin and gross cystic duct fluid protein should be performed on the biopsy material in such patients. In addition to physical examination of both breasts, mammography is indicated to search for the primary site. A clinically occult breast cancer will be found in approximately one-third of cases. Bilateral breast MRI is indicated if mammography is negative; an occult breast cancer may be found in about 75 percent of such cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link&amp;anchor=H8#H8\">",
"     \"Axillary node metastases with occult primary breast cancer\", section on 'Breast MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a focal lesion is identified, further diagnostic evaluation should follow standard guidelines for suspected breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with adenocarcinoma or poorly differentiated carcinoma in axillary nodes, compatible IHC staining, no other distant metastases, and no evidence of a breast cancer primary on clinical examination, mammography, or breast MRI represent a potentially curable subset of individuals with adenocarcinoma of unknown primary site. These patients are treated according to guidelines for stage II breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link&amp;anchor=H11#H11\">",
"     \"Axillary node metastases with occult primary breast cancer\", section on 'Locoregional treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who present with adenocarcinoma or poorly differentiated carcinoma in the axillary nodes, compatible IHC staining, no evident primary breast tumor, and who have metastatic sites in addition to axillary lymph nodes may have metastatic breast cancer. These women should receive a trial of systemic therapy according to guidelines for the treatment of metastatic breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link&amp;anchor=H18#H18\">",
"     \"Axillary node metastases with occult primary breast cancer\", section on 'Metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Men with skeletal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;When bone metastases are the first manifestation of metastatic adenocarcinoma, the most common primary tumor sites are the lung, prostate, and less often, liver, kidney, thyroid, and colon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metastatic prostate cancer should be suspected in men with adenocarcinoma predominantly involving bone, particularly if the metastases are blastic or sclerotic (",
"    <a class=\"graphic graphic_table graphicRef54124 \" href=\"UTD.htm?21/17/21787\">",
"     table 6",
"    </a>",
"    ). Elevated serum levels of PSA or tumor staining with PSA provide confirmatory evidence of prostate cancer. Occasional patients have a significantly elevated serum PSA or tumor staining for PSA, but a clinical presentation that is atypical for prostate cancer (eg, metastases to the lung or mediastinal or upper abdominal lymph nodes, without concomitant involvement of bone or pelvic lymph nodes) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41622?source=see_link\">",
"     \"Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metastatic prostate cancer is amenable to treatment with a range of therapies that differ from those used for metastatic adenocarcinoma of other primary sites, and these patients should be treated according to guidelines for advanced prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519862394\">",
"    <span class=\"h2\">",
"     Patients with a colon cancer profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current approaches to systemic treatment for patients with metastatic colorectal cancer have resulted in a substantial improvement in overall survival compared with earlier regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44058?source=see_link\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accurate recognition of adenocarcinoma patients who are likely to respond to similar treatments is therefore increasingly important. A \"colon cancer profile\" has been defined and includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predominant metastatic sites in the liver",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peritoneum",
"     </li>",
"     <li>",
"      Adenocarcinoma with histology typical of gastrointestinal origin",
"     </li>",
"     <li>",
"      Typical immunohistochemical staining pattern including",
"      <span class=\"nowrap\">",
"       CK20-positive/CK7-negative",
"      </span>",
"      or CDX-2 positive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with this profile respond well to chemotherapy with contemporary regimens developed for patients with metastatic colorectal carcinoma (eg,",
"    <span class=\"nowrap\">",
"     FOLFOX/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"      bevacizumab",
"     </a>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing evidence supports the use of site-specific treatment of CUP patients who have a colorectal tissue of origin identified by gene expression profiling. In two retrospective series, CUP patients who were predicted to have colorectal cancer and received standard regimens for advanced colon cancer had median survival &gt;20 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In both series, approximately 45 percent of patients had atypical IHC staining, and would not have been identified by standard pathologic evaluation. Although prospective data is needed, the survival documented in these retrospective studies, which is similar to patients with advanced colon cancer, suggests accurate identification by molecular profiling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adenocarcinoma of unknown primary in a single site",
"    </span>",
"    &nbsp;&mdash;&nbsp;In occasional patients, only a single metastatic lesion is identified after a complete staging evaluation. Such single lesions have been described in a variety of sites including lymph nodes, brain, lung, adrenal gland, liver, and bone. The possibility of an unusual primary site (eg, apocrine, eccrine, or sebaceous carcinoma) mimicking a metastatic lesion should be considered, but can usually be excluded on the basis of clinical or pathologic features.",
"   </p>",
"   <p>",
"    In most of these patients, other metastatic sites become evident within a relatively short time. A PET scan may be helpful to rule out additional unrecognized sites of metastatic disease prior to definitive local therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Initial clinical evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If no evidence of additional disease is found, resection of the solitary lesion should be considered. If resection is not feasible because of the location of the metastatic lesion, definitive local radiation therapy should be administered. Local treatment sometimes results in prolonged disease-free intervals.",
"   </p>",
"   <p>",
"    In some instances (eg, after resection of a solitary brain metastasis), local radiation therapy may also be appropriate to maximize the chance of local control [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of adjuvant chemotherapy in this setting is undefined. Patients with poorly differentiated carcinoma may benefit from platinum-based therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H315626628\">",
"    <span class=\"h1\">",
"     TREATMENT FOR PATIENTS NOT INCLUDED IN SPECIFIC SUBGROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with adenocarcinoma of unknown primary site do not fit into any of the clinical subgroups outlined above. As treatment for specific types of advanced cancer improves, the accurate identification of the tissue of origin, followed by site-specific therapy, is likely to improve treatment results for patients with CUP.",
"   </p>",
"   <p>",
"    Examples of patients in whom site-specific therapy would be different and more effective than empiric CUP therapy include those with colorectal cancer or kidney cancer. In addition, accurate prediction of the tissue of origin could lead to appropriate testing for actionable gene mutations. For example, a prediction of non-small cell lung cancer could lead to the identification of an EGFR or ALK mutation, with specific therapeutic implications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=see_link\">",
"     \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H315626636\">",
"    <span class=\"h2\">",
"     Site-specific therapy directed by molecular tumor profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown that molecular profiling can predict a tissue of origin in the large majority of patients with CUP, and that predictions are usually consistent with the clinical presentation. Evidence supporting the use of site-specific therapy directed by the results of molecular tumor profiling is incomplete but is becoming increasingly compelling. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Molecular tumor profiling'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As an example, in a prospective study, newly diagnosed, previously untreated patients with CUP had tumor biopsy material submitted for a 92-gene RT-PCR cancer classification assay and then received site-specific treatment based upon the assay prediction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/42\">",
"     42",
"    </a>",
"    ]. Of the 252 patients whose biopsies contained sufficient tumor, 247 (98 percent) had a tissue of origin predicted.",
"   </p>",
"   <p>",
"    Twenty-six different sites of origin were predicted by the assay; however, the seven most common diagnoses (biliary tract, urothelium, colorectum, non-small cell lung, pancreas, breast, ovary) accounted for 69 percent of cases. The median survival of the 194 patients who received site-specific therapy was 12.5 months. Patients who had predictions of more responsive tumor types had longer median survival than those with less responsive types (13.4 versus 7.6 months; p = 0.04). The median survival of patient groups with different specific tumor predictions varied widely, and generally mirrored the expected survival of patients with the predicted cancer types (biliary tract 7 months, pancreas 8 months, colon 13 months, ovarian 30 months, and breast cancer not reached at &gt;24 months).",
"   </p>",
"   <p>",
"    The results of this prospective trial demonstrate that site-specific therapy directed by molecular tumor profiling is feasible, and led to a median survival in a large group of CUP patients that compares favorably to the historical results in which patients were treated with empiric drug regimens. Patients with the potential to benefit most from site-specific therapy (ie, those with sensitive tumor types) could be identified and treated appropriately.",
"   </p>",
"   <p>",
"    Although a randomized trial is the only way to provide a definitive answer to this question, the available data strongly suggest that site-directed therapy directed by molecular tumor profiling improves outcome for patients with CUP. Molecular tumor profiling should be considered in the standard diagnostic workup of patients with CUP, and subsequent site-specific therapy is recommended, particularly in patients predicted to have responsive tumor types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric chemotherapy remains the treatment of choice for the small minority of patients in whom a tissue of origin cannot be predicted after a complete diagnostic evaluation that includes molecular tumor profiling.",
"   </p>",
"   <p>",
"    Several two-drug combinations are reasonable choices for first-line therapy, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus carboplatin, and gemcitabine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. These regimens produce response rates of 25 to 45 percent, with median survivals of 7 to 10 months. In a composite group of 396 patients treated in 5 consecutive clinical trials by the Minnie Pearl Network, the median survival was 9 months, with a 19 percent 2-year survival rate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/43\">",
"     43",
"    </a>",
"    ]. The addition of a third cytotoxic agent increases toxicity and has not been shown to improve efficacy. Patients with poor performance status are much less likely to benefit from chemotherapy, and optimal management in these cases may be limited to supportive measures.",
"   </p>",
"   <p>",
"    A few second-line empiric regimens have been evaluated in phase II trials, usually following first-line",
"    <span class=\"nowrap\">",
"     taxane/platinum",
"    </span>",
"    combinations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Modest activity was seen with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"      oxaliplatin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"      capecitabine",
"     </a>",
"    </span>",
"    (20 percent response rate, median survival 9.7 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/48\">",
"     48",
"    </a>",
"    ]and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"      gemcitabine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"      irinotecan",
"     </a>",
"    </span>",
"    (10 percent response rate, median survival 4.5 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/50\">",
"     50",
"    </a>",
"    ]. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    also had activity, with a 10 percent response rate and median survival 7.4 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective analyses have identified clinical and pathologic features that are associated with a favorable response to treatment using empiric chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/51-57\">",
"     51-57",
"    </a>",
"    ]. Many of these features are related to tumor grade or extent of disease, and are prognostic factors for many types of advanced cancer. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor location in lymph nodes or soft tissue. Patients with involvement of the liver or bones have relatively poor prognosis.",
"     </li>",
"     <li>",
"      Fewer sites of metastatic disease",
"     </li>",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Poorly differentiated carcinoma histology",
"     </li>",
"     <li>",
"      Good performance status",
"     </li>",
"     <li>",
"      Normal serum lactate dehydrogenase (LDH) level",
"     </li>",
"     <li>",
"      Normal serum albumin",
"     </li>",
"     <li>",
"      Normal lymphocyte count",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one prognostic factor analysis that included 150 patients with CUP who were seen at a single institution over a 10 year period, the performance status (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ) and serum LDH could be used to separate patients into good and poor risk categories. The median survival durations were 11.7 and 3.9 months, and one-year survival rates were 45 and 11 percent, for good and poor risk patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multivariate analysis of prognostic factors based upon a series of 317 consecutive patients found that a normal serum albumin and the absence of liver metastases identified a favorable subset of patients (median survival 371 versus 103 days, in patients with a low serum albumin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver metastases) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28121/abstract/56\">",
"     56",
"    </a>",
"    ]. In the same report, the favorable prognosis associated with the combination of a normal serum albumin and the absence of liver metastases was validated in a second patient cohort of 124 patients with CUP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment paradigm for patients with CUP is evolving (",
"    <a class=\"graphic graphic_algorithm graphicRef86664 \" href=\"UTD.htm?21/19/21822\">",
"     algorithm 1",
"    </a>",
"    ). The era of empiric chemotherapy is nearing its end and is being replaced by site-specific therapy directed by improved diagnostic techniques.",
"   </p>",
"   <p>",
"    Foremost among these improvements are molecular tumor profiling assays, which predict a site of origin in most CUP patients. Although the confirmation of improved treatment outcome as a result of molecular tumor profiling is incomplete, the current data are strong enough to recommend this approach. Empiric chemotherapy remains the treatment of choice for patients in whom molecular profiling fails to predict a tissue of origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with adenocarcinoma of unknown primary site should be evaluated to determine whether their clinical features and pathology classify them as belonging to any of the following subsets for which individualized therapy is appropriate:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women with adenocarcinoma of unknown primary and peritoneal carcinomatosis and consistent pathology should be treated like those with ovarian carcinoma. This approach may include both surgical debulking and systemic chemotherapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Women with peritoneal carcinomatosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H7#H7\">",
"       \"Epithelial ovarian cancer: Initial surgical management\", section on 'Cytoreduction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women presenting with adenocarcinoma of unknown primary and axillary lymphadenopathy should be treated as if they have primary breast cancer, as long as the pathology and clinical presentation are consistent with that diagnosis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Women with axillary lymph node metastases'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link\">",
"       \"Axillary node metastases with occult primary breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men with metastatic adenocarcinoma and elevated serum levels of PSA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tumor staining with PSA should be treated for advanced prostate cancer. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Men with skeletal metastases'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"       \"Overview of the treatment of disseminated prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who present with a colon cancer profile (ie, predominant metastatic sites in the liver",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peritoneum, an adenocarcinoma with histology typical of gastrointestinal origin, and typical immunohistochemical staining pattern",
"      <span class=\"nowrap\">",
"       [CK20-positive/CK7-negative,",
"      </span>",
"      or CDX-2 positive]) should be treated as if they have metastatic colorectal cancer. Treatment for colorectal cancer should also be considered for patients with a colorectal tissue of origin predicted by gene expression profiling. (See",
"      <a class=\"local\" href=\"#H519862394\">",
"       'Patients with a colon cancer profile'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44058?source=see_link\">",
"       \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a single metastatic focus of adenocarcinoma should be carefully evaluated to exclude any other sites of disease involvement. If no other site of disease involvement can be identified, we recommend definitive local therapy, consisting of either surgical resection or radiation therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although most patients will develop disseminated disease relatively rapidly, this approach is associated with prolonged survival in some cases. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Adenocarcinoma of unknown primary in a single site'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who do not fit into any of the specific subsets should have complete pathologic evaluation including molecular tumor profiling. &nbsp;If a tissue of origin is predicted, site-specific therapy for the tumor type predicted should be considered. Patients who have a good performance status and in whom complete diagnostic evaluation does not predict a tissue of origin should receive a trial of empiric chemotherapy using contemporary agents. We prefer either a",
"      <span class=\"nowrap\">",
"       platinum/taxane",
"      </span>",
"      or a",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"        gemcitabine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"        irinotecan",
"       </a>",
"      </span>",
"      combination. (See",
"      <a class=\"local\" href=\"#H315626628\">",
"       'Treatment for patients not included in specific subgroups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be enrolled in formal clinical studies whenever possible.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/1\">",
"      Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin Oncol 2009; 36:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/2\">",
"      Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007; 43:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/3\">",
"      Hammar SP. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol 1998; 29:1393.",
"     </a>",
"    </li>",
"    <li>",
"     Dabbs D. Diagnostic immunohistochemistry, Churchill Livingstone, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/5\">",
"      Bohinski RJ, Bejarano PA, Balko G, et al. Determination of lung as the primary site of cerebral metastatic adenocarcinomas using monoclonal antibody to thyroid transcription factor-1. J Neurooncol 1998; 40:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/6\">",
"      Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000; 36:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/7\">",
"      Gomez-Fernandez C, Jorda M, Delgado PI, Ganjei-Azar P. Thyroid transcription factor 1: a marker for lung adenoarinoma in body cavity fluids. Cancer 2002; 96:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/8\">",
"      Brown RW, Campagna LB, Dunn JK, Cagle PT. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997; 107:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/9\">",
"      Kaufmann O, Deidesheimer T, Muehlenberg M, et al. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology 1996; 29:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/10\">",
"      Lagendijk JH, Mullink H, Van Diest PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998; 29:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/11\">",
"      Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer 1999; 85:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/12\">",
"      Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001; 61:7388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/13\">",
"      Bender RA, Erlander MG. Molecular classification of unknown primary cancer. Semin Oncol 2009; 36:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/14\">",
"      Erlander MG, Ma XJ, Kesty NC, et al. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn 2011; 13:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/15\">",
"      Pillai R, Deeter R, Rigl CT, et al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn 2011; 13:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/16\">",
"      Meiri E, Mueller WC, Rosenwald S, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 2012; 17:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/17\">",
"      Varadhachary GR, Talantov D, Raber MN, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008; 26:4442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/18\">",
"      Horlings HM, van Laar RK, Kerst JM, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008; 26:4435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/19\">",
"      Greco FA, Spigel DR, Yardley DA, et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010; 15:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/20\">",
"      Hainsworth JD, Schnabel CA, Erlander MG, et al. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 2012; 11:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/21\">",
"      Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2013; 31:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/22\">",
"      Shildt RA, Kennedy PS, Chen TT, et al. Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study. Cancer Treat Rep 1983; 67:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/23\">",
"      S&egrave;ve P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/24\">",
"      Moller AK, Loft A, Berthelsen AK, et al. 18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review. Oncologist 2011; 16:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/25\">",
"      Currow DC, Findlay M, Cox K, Harnett PR. Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. Eur J Cancer 1996; 32A:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/26\">",
"      Pavlidis N, Kalef-Ezra J, Briassoulis E, et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 1994; 22:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/27\">",
"      Schorge JO, Muto MG, Welch WR, et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998; 90:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/28\">",
"      Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/29\">",
"      Dauplat J, Le Bou&euml;dec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol 2000; 19:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/30\">",
"      Strnad CM, Grosh WW, Baxter J, et al. Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 1989; 111:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/31\">",
"      Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989; 64:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/32\">",
"      Ransom DT, Patel SR, Keeney GL, et al. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer 1990; 66:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/33\">",
"      Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990; 75:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/34\">",
"      Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993; 50:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/35\">",
"      Katagiri H, Takahashi M, Inagaki J, et al. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study. Cancer 1999; 86:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/36\">",
"      Gentile PS, Carloss HW, Huang TY, et al. Disseminated prostatic carcinoma simulating primary lung cancer. Indications for immunodiagnostic studies. Cancer 1988; 62:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/37\">",
"      Tell DT, Khoury JM, Taylor HG, Veasey SP. Atypical metastasis from prostate cancer. Clinical utility of the immunoperoxidase technique for prostate-specific antigen. JAMA 1985; 253:3574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/38\">",
"      Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 2008; 9:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/39\">",
"      Rades D, K&uuml;hnel G, Wildfang I, et al. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001; 12:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/40\">",
"      Nguyen LN, Maor MH, Oswald MJ. Brain metastases as the only manifestation of an undetected primary tumor. Cancer 1998; 83:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/41\">",
"      Salvati M, Cervoni L, Raco A. Single brain metastases from unknown primary malignancies in CT-era. J Neurooncol 1995; 23:75.",
"     </a>",
"    </li>",
"    <li>",
"     Greco FA, Rubin MS, Boccia RV, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients (pts) with carcinoma of unknown primary site (CUP): Results of a prospective Sarah Cannon Research Institute (SCRI) trial. J Clin Oncol 2012; 30: (suppl; abstr 10530).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/43\">",
"      Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 2009; 36:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/44\">",
"      Huebner G, Link H, Kohne CH, et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 2009; 100:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/45\">",
"      Yonemori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. Br J Cancer 2009; 100:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/46\">",
"      Palmeri S, Lorusso V, Palmeri L, et al. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study. Cancer 2006; 107:2898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/47\">",
"      Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J 2010; 16:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/48\">",
"      Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010; 116:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/49\">",
"      Hainsworth JD, Spigel DR, Farley C, et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 2007; 25:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/50\">",
"      Hainsworth JD, Spigel DR, Raefsky EL, et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer 2005; 104:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/51\">",
"      Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/52\">",
"      Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/53\">",
"      Saghatchian M, Fizazi K, Borel C, et al. Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. Ann Oncol 2001; 12:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/54\">",
"      van der Gaast A, Verweij J, Henzen-Logmans SC, et al. Carcinoma of unknown primary: identification of a treatable subset? Ann Oncol 1990; 1:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/55\">",
"      Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20:4679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/56\">",
"      Seve P, Ray-Coquard I, Trillet-Lenoir V, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 2006; 107:2698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28121/abstract/57\">",
"      Kodaira M, Takahashi S, Yamada S, et al. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Ann Oncol 2010; 21:1163.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4877 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28121=[""].join("\n");
var outline_f27_29_28121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Poorly differentiated adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Molecular tumor profiling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INITIAL CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SPECIFIC PATIENT SUBGROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Women with peritoneal carcinomatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pathology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Women with axillary lymph node metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Men with skeletal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H519862394\">",
"      Patients with a colon cancer profile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adenocarcinoma of unknown primary in a single site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H315626628\">",
"      TREATMENT FOR PATIENTS NOT INCLUDED IN SPECIFIC SUBGROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H315626636\">",
"      Site-specific therapy directed by molecular tumor profiling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4877\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4877|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/19/21822\" title=\"algorithm 1\">",
"      Treatment of patients with carcinoma of unknown primary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4877|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/49/30482\" title=\"figure 1\">",
"      Immunohistochem CUP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4877|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/34/11821\" title=\"table 2\">",
"      Surv unkn primary ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23980\" title=\"table 3\">",
"      CUP immunostaining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29932\" title=\"table 4\">",
"      Immunohistochemistry CUP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/45/21212\" title=\"table 5\">",
"      Cytokeratin stain pattern CUP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/17/21787\" title=\"table 6\">",
"      Typical radiographic response in bone to select tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=related_link\">",
"      Axillary node metastases with occult primary breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41622?source=related_link\">",
"      Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=related_link\">",
"      Overview of the classification and management of cancers of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=related_link\">",
"      Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_29_28122="Nocturia: Clinical presentation, diagnosis, and treatment";
var content_f27_29_28122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nocturia: Clinical presentation, diagnosis, and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28122/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28122/contributors\">",
"     Theodore M Johnson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28122/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28122/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/29/28122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/29/28122/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/29/28122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturia, a common symptom, is defined as waking at night to void, where each micturition is preceded and followed by sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/1\">",
"     1",
"    </a>",
"    ]. Although by definition even a single episode of awakening to urinate is nocturia, epidemiological evidence and expert clinical opinion both suggest nocturia is likely clinically meaningful if a patient voids two or more times nightly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients themselves are more likely to consult a provider about nocturia if they have three or more episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/3\">",
"     3",
"    </a>",
"    ]. Nocturnal urinary incontinence or nighttime bed-wetting (enuresis) is distinct from nocturia.",
"   </p>",
"   <p>",
"    Nocturia is a source of significant bother for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/4\">",
"     4",
"    </a>",
"    ]. Nocturia is one of the most distressing symptoms in older men with benign prostatic hyperplasia (BPH) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/5\">",
"     5",
"    </a>",
"    ] and is the lower urinary tract symptom most strongly associated with poor quality of life ratings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients report nocturia as a leading cause of sleep disturbance, affecting both sleep onset and maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/7\">",
"     7",
"    </a>",
"    ]. Nocturia is associated with increased rates of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/8\">",
"     8",
"    </a>",
"    ], work absenteeism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/9\">",
"     9",
"    </a>",
"    ], lower self-rated physical and mental health [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/10\">",
"     10",
"    </a>",
"    ], congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/11\">",
"     11",
"    </a>",
"    ], and increased all cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/12\">",
"     12",
"    </a>",
"    ]. In the very old, nocturia is associated with higher rates of accidental falls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/13,14\">",
"     13,14",
"    </a>",
"    ] and fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because nocturia is associated with a variety of clinical syndromes and disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/17\">",
"     17",
"    </a>",
"    ], the diagnostic approach is often challenging, and treatment may result in only small improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the clinical presentation, diagnosis, and treatment of nocturia in adults. Detailed discussions of some conditions that cause or are associated with nocturia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of nocturia is higher with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/10,19-21\">",
"     10,19-21",
"    </a>",
"    ]. Occasional nocturia is present in 50 percent of men and women aged 50 to 59 years. Among 18 to 49 year olds, more women than men have nocturia; the sex ratio reverses after 60 years of age, with prevalence greater in men than women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/19\">",
"     19",
"    </a>",
"    ]. The prevalence of twice nightly or greater nocturia among men between 70 and 79 is nearly 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies indicate that the prevalence of nocturia is higher in non-Hispanic black men and women, with Hispanic men and women having an intermediate prevalence compared to non-Hispanic whites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Higher rates of nocturia in black men and women do not appear to be due to socioeconomic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a group of men aged 50 to 70 followed longitudinally, the risk for developing nocturia was highest in 70-year olds and lowest for the 50-year olds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/25\">",
"     25",
"    </a>",
"    ]. Every year, approximately 10 percent more men started to void during the night. Also, older men were much less likely to have a remission of their nocturia when compared to the younger men. Fluctuations in the symptom make it difficult to provide a reliable incident rate. While pregnant women commonly have nocturia, it nearly always resolves by three months post partum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for nocturia include obesity, hypertension, diuretic usage, snoring, restless leg syndrome, BPH, prostate cancer, antidepressant usage, coronary artery disease, congestive heart failure, and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/10,27,28\">",
"     10,27,28",
"    </a>",
"    ]. Although nocturia has been associated with increased mortality (15-year survival rates of 76.5 and 84.8 percent for individuals with and without nocturia, respectively), this association is not confirmed by multivariate analysis correcting for hypertension, diabetes, chronic pulmonary disease, cardiac symptoms, smoking, and age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may initiate a discussion of their sleep being interrupted by nighttime voiding, or the clinician might learn of nocturia during a review of symptoms. Clinicians should specifically question about \"waking at night to urinate\" (or &ldquo;to pee,&rdquo; &ldquo;to void,&rdquo; or &ldquo;to make water&rdquo;) since nearly one-half of patients do not correctly interpret the term \"nocturia\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/30\">",
"     30",
"    </a>",
"    ]. Occasionally, nocturia can be an indicator of worsening clinical status of an underlying disease, such as renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/31\">",
"     31",
"    </a>",
"    ], diabetes mellitus, or congestive heart failure. The most important reason to diagnose nocturia, however, is to address symptoms and minimize its negative impact on quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nocturia is insidious in its onset. Few patients present with an abrupt onset of three to four episodes of nocturia nightly; most individuals describe progressing from having an episode occasionally to having one or more episodes nightly. Additionally, nocturia has a varied night-to-night occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/25\">",
"     25",
"    </a>",
"    ]. For some patients, this unpredictability represents another loss of control in the process of aging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/33\">",
"     33",
"    </a>",
"    ], and makes it difficult to predict how much sleep a patient can expect in any given night [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is more valuable to quantify and understand how much distress nocturia causes the patient, than to focus on obtaining a precise count of nightly episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/35\">",
"     35",
"    </a>",
"    ]. While frequency of episodes and \"bother\" from nocturia are linked, one study of men with BPH found that the number of nightly nocturia episodes explained only 25 percent of the variance in reported bother. Other factors, such as difficulty returning to sleep following nighttime awakening, and degree of morning fatigue, contribute to the impact of nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturia can be attributed to any disorder or condition that causes one of the following (",
"    <a class=\"graphic graphic_table graphicRef67664 \" href=\"UTD.htm?41/8/42124\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low volume bladder void",
"     </li>",
"     <li>",
"      Increased volume of nighttime urinary output",
"     </li>",
"     <li>",
"      Sleep disturbance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 41 male patients (mean age 72.5 years) with two or more nocturnal micturitions, the following etiologies were found: nocturnal polyuria 83 percent; low bladder volume capacity 58 percent; bladder outlet obstruction 44 percent; sleep apnea 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/38\">",
"     38",
"    </a>",
"    ]. A study of 845 patients with symptoms of overactive bladder and nocturia found that younger patients (&lt; 50 years) were more likely to have low bladder capacity, and older patients (&gt;70 years) more likely to have increased nocturnal urine output, based on data from a 7-day voiding diary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For many patients with nocturia, it is likely that multiple conditions coexist and lead to symptoms. As an example, a study of 55 patients evaluating comorbid illness found that male patients (mean age 67 years) had an average of 4.5 medical conditions likely to be related to nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Low volume bladder voids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low volume voids may be due either to reduced bladder capacity or impaired bladder function. The two most common causes of low volume bladder voids are an overactive bladder, and bladder outlet obstruction, often related to benign prostatic hypertrophy.",
"   </p>",
"   <p>",
"    Increased age has been associated with reduced bladder volume; it is unclear if this is due to age-related changes in the bladder or to the high prevalence of detrusor hyperactivity in the older population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/41\">",
"     41",
"    </a>",
"    ]. Since so many older adults have detrusor hyperactivity, it often appears that aging is associated with small volume voids (since this is a result from detrusor hyperactivity). When the separate effects of age and bladder pathophysiology are carefully teased apart, older women without detrusor hyperactivity appear to have normal bladder capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/42\">",
"     42",
"    </a>",
"    ]. Increased age is also associated with increased prevalence of BPH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34104?source=see_link\">",
"     \"Epidemiology and pathogenesis of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Increased nighttime urinary volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in urinary volume at night may be due to an increase in the total 24-hour urine output, or to a higher percentage of the total daily urine output being excreted at night.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nocturnal polyuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pattern of urination is a decrease in nighttime, relative to daytime, urine output. Overproduction of urine at night, with a normal 24 hour urine output, is called nocturnal polyuria. This is defined as the nighttime excretion of 35 percent or more of a 24-hour volume of urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Role of arginine vasopressin &mdash; Nocturnal polyuria may be due to age-related changes in the secretion and action of arginine vasopressin (AVP) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. AVP, a peptide hormone secreted by the neurohypophyseal system, is released when plasma osmolality is increased or blood pressure decreased (as seen with orthostasis, vasodilation, or significant blood loss). AVP targets receptors in the renal distal tubules which control urine concentration. There is a diurnal periodicity in AVP release in young healthy subjects, with higher AVP plasma levels in the evening contributing to decreased nighttime urine output [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/46\">",
"       46",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The diurnal variation in AVP release is absent in many older subjects. A study of 69 healthy subjects whose plasma AVP and osmolality were monitored every four hours found that older subjects who maintained a normal diurnal pattern in AVP had no episodes of nocturia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/47\">",
"       47",
"      </a>",
"      ]. Another study compared diurnal AVP variation in 17 men referred for nocturia believed to be related to BPH with 10 men with no nocturia symptoms; 11 of the 17 men with nocturia exhibited absent diurnal variation in AVP, compared with 0 of 10 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Solute diuresis &mdash; Dietary solutes (principally, urea, sodium, and potassium) are excreted soon after a meal; decreased solute excretion at night is another factor accounting for relatively low nocturnal urine output in healthy adults. Disorders in solute diuresis, associated with certain disease states, can lead to nocturnal polyuria.",
"     </li>",
"     <li>",
"      Heart failure or other edematous states (nephrotic syndrome and venous insufficiency) causes third spacing of fluids. Assumption of the supine position permits mobilization of some of the edema fluid into the vascular space, and leads to a solute diuresis.",
"     </li>",
"     <li>",
"      Autonomic dysfunction can increase urinary sodium excretion related to reduced sympathetic activity, resulting in a solute diuresis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/17\">",
"       17",
"      </a>",
"      ]. Nocturnal polyuria is a frequent symptom of Parkinson disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Polyuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Global polyuria is defined as a 24-hour urine volume that exceeds 3 liters per day (or 40 mL per kg). Causes of polyuria (both day and night) include uncontrolled diabetes mellitus, diabetes insipidus, and primary polydipsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sleep disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturia occurs in approximately 50 percent of patients with obstructive sleep apnea syndrome (OSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/50\">",
"     50",
"    </a>",
"    ]. OSA should be considered as a possible diagnosis in patients with nocturia, and the close association between the conditions has led to a suggestion that nocturia should be a screening questionnaire for OSAS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/51\">",
"     51",
"    </a>",
"    ]. Sleep disorders have been demonstrated to be a frequent cause of nocturia in men younger than 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/52\">",
"     52",
"    </a>",
"    ] and in women with symptoms of daytime overactive bladder syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/53\">",
"     53",
"    </a>",
"    ]. Primary sleep disorders may result in nocturia either because of hormonal changes related to sleep disordered breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/54\">",
"     54",
"    </a>",
"    ], or to patient misperception of the reason for awakening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a primary sleep problem (OSAS, restless leg syndrome, and periodic limb movements at night) may awaken due to the sleep disturbance but recall this as an awakening to void. In a study in a sleep clinic population where participants were monitored with overnight polysomnography, of participants who identified \"needing to void\" as the reason they awoke, the polysomnographic record showed that an apneic episode, snoring, or restless leg movement immediately preceded the awakening in 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obstructive sleep apnea may also cause nocturnal polyuria by release of atrial natriuretic peptide (ANP) due to negative intrathoracic pressure and stretching of the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/56\">",
"     56",
"    </a>",
"    ]. ANP release causes vasodilation and inhibits aldosterone, resulting in increased sodium and water excretion. ANP levels are elevated in patients with obstructive sleep apnea and nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/57,58\">",
"     57,58",
"    </a>",
"    ] and are reduced with use of CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of nocturia is increased in patients with untreated depression. A longitudinal study of 2000 men aged 50 to 70 years old found a relative risk of 2.8 (95% CI 1.5 to 5.2) for developing nocturia over five years for men with depressive symptoms at study entry, compared to men with no baseline depression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/59\">",
"     59",
"    </a>",
"    ]. Associations between symptoms of depression and nocturia have been demonstrated for adult women (nearly twice the odds, shown in two separate studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/8,60\">",
"     8,60",
"    </a>",
"    ] and, in a single study, nearly triple the odds in men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/60\">",
"     60",
"    </a>",
"    ]. It is not known whether treatment for depression would impact the development of nocturia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal adiposity is associated with a slight increased risk of having two or more episodes of nocturia (OR 1.16 comparing highest and lowest quartile) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/61\">",
"     61",
"    </a>",
"    ]. Measured abdominal girth may be more important than body mass index.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nocturia should have a targeted evaluation that extends beyond the bladder (",
"    <a class=\"graphic graphic_table graphicRef82467 \" href=\"UTD.htm?41/18/42284\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;One question from the American Urologic Association Seven Symptom Index (AUA-7 SI) is used frequently in clinical and research settings to identify patients with nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/62\">",
"     62",
"    </a>",
"    ]: \"Over the past month, how often did you most typically get up at night to urinate from the time you went to bed at night until the time you got up in the morning?\" The validity of this question, compared to diaries and 24-hour monitoring, has been confirmed in some [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/63,64\">",
"     63,64",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/65\">",
"     65",
"    </a>",
"    ], studies.",
"   </p>",
"   <p>",
"    For most clinical purposes, the question can be shortened to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"On average, how many times do you wake up at night to void?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important to determine the bother or disruption caused by the nocturia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Over the past month, how much has getting up at night to urinate been a problem for you?\" (No problem, very small problem, small problem, medium problem, or large problem)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a history of nocturia is elicited, information should be obtained regarding patterns and types of fluid intake, medications, comorbid medical conditions, and urinary tract symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fluid intake",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-four hour fluid intake &mdash; Patients should be asked about the amount and types of their fluid intake. Large fluid intakes (&gt;40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per day) may be responsible for nocturia. Follow-up questions about the reason for the large fluid intake (psychogenic, history of renal stones, vigorous outdoor exercise, general health belief about fluid intake, attempt at weight loss, diabetes insipidus) are important in developing the treatment plan.",
"     </li>",
"     <li>",
"      Fluid intake at bedtime &mdash; Patients may drink large volumes immediately prior to bedtime. Although clinicians should make a recommendation to reduce nighttime fluid intake, patients will often have initiated this on their own prior to seeking help. Care should be taken not to further restrict fluid intake in older patients who have borderline or inadequate fluid intake to meet daily needs.",
"     </li>",
"     <li>",
"      Intake of diuretic fluids &mdash; Patients should be asked about caffeine or alcohol intake prior to bedtime. Both of these substances may predispose patients to sleep disruption at night. Caffeine usage may result in polyuria or detrusor overactivity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescription and over-the-counter medications, and their temporal relationship to nocturia onset or worsening, should be evaluated. In particular, patients who take twice daily loop diuretics may be helped by switching the nighttime dosage to a mid-afternoon dosage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Xanthines and beta blockers have been associated with bladder storage problems. Cholinesterase inhibitors used for the treatment of dementia may result in worsening of lower urinary tract symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/68\">",
"     68",
"    </a>",
"    ]. Conversely, some older patients given anticholinergic medications for bladder symptoms may experience worsening cognitive impairment or delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturia is independently associated with hypertension, diuretic usage, and diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/27\">",
"     27",
"    </a>",
"    ]. A history should also be obtained about congestive heart failure, peripheral edema, depression, sleep problems, and nighttime pain.",
"   </p>",
"   <p>",
"    The presence of dizziness may impact the ability to prescribe alpha-blocker therapy in men. Issues related to safe ambulation at night and past history of accidental falls or injuries from falling should be explored, particularly in older individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Urinary tract symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questions should be asked about other lower urinary tract symptoms, including obstructive symptoms (hesitancy, weak stream, incomplete emptying, or intermittency), irritative symptoms (urinary frequency, urgency), and urinary incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive examination, similar to that performed in the evaluation of urinary incontinence, is indicated to detect underlying health conditions and contributory factors relevant to nocturia. The following are key points in the physical examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orthostatic vital signs are useful to measure. For older men, orthostatic hypotension and complaints of dizziness on rising are relevant when prescribing alpha-blocker medications for BPH.",
"     </li>",
"     <li>",
"      The cardiovascular and pulmonary examinations should focus on evidence of volume overload or congestive heart failure.",
"     </li>",
"     <li>",
"      The abdomen should be palpated for suprapubic masses and tenderness, although physical examination is an insensitive test for bladder distention due to an abnormally high post-void residual.",
"     </li>",
"     <li>",
"      The rectal examination should focus on the detection of fecal impaction, resting and volitional rectal tone, and gross estimation of prostate size (a precise determination of prostate size by digital examination is difficult). During the rectal examination, patients can be taught how to contract their pelvic floor muscles while keeping their abdominal muscles relaxed. This skill can be incorporated into urge suppression strategies.",
"     </li>",
"     <li>",
"      The lower extremities should be examined for the presence of pitting edema.",
"     </li>",
"     <li>",
"      The neurological examination should include an evaluation of sacral root integrity by testing perineal sensation and anal wink (visual or palpated anal contraction in response to a light scratch of the perineal skin lateral to the anus).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Frequency-volume chart",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient's report of average episodes of nocturia and the degree of bother is usually adequate to assess the response to therapy. A 24-hour recording of void time and void amount, along with times of going to bed and awakenings, can be extremely helpful in patients who have not adequately responded to initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/37\">",
"     37",
"    </a>",
"    ], although patients may find this difficult to perform properly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/63\">",
"     63",
"    </a>",
"    ]. Such a record can help determine whether nocturia is due to low volume voiding at night, increased nocturnal polyuria, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/71\">",
"     71",
"    </a>",
"    ]. The record provides useful diagnostic and therapeutic clues, including the maximal voided volume (a measure of functional bladder capacity) and modal voided volume, and can identify patients with high volume fluid intake (&ge; 3 liters) who did not report this in their history. A sample log is provided (",
"    <a class=\"graphic graphic_form graphicRef64573 \" href=\"UTD.htm?33/7/33906\">",
"     form 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Interpretation of these records requires understanding some conventions. Nocturia episodes are voids that occur between going to bed and rising in the morning. The first morning void is not counted as a nocturia episode. Nighttime urine output includes any volume produced after bedtime, so this calculation does include the first morning void. Thus, if the nocturnal urine output (amount voided during hours of sleep plus the first morning void) is 1200 mL and the modal voided volume is 300 mL, then the patient probably has three episodes of nocturia (1200 &divide; 300 = 4) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/37\">",
"     37",
"    </a>",
"    ]. The fourth void takes place as the first morning void, and is not counted as nocturia.",
"   </p>",
"   <p>",
"    If the nighttime urine volume (1200 mL in this example, including the first morning void) divided by the 24-hour urine volume is greater than 35 percent, the patient has nocturnal polyuria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/43\">",
"     43",
"    </a>",
"    ]. Older individuals with nocturia, compared to older individuals without nocturia, have smaller average volume voids and a greater percentage of their urine output is excreted at night [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the voiding record shows that the 24-hour urine output is higher than expected, it is important to confirm fluid intake. A log of the patient's complete fluid intake may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with neurological conditions affecting the bladder (including diabetic neuropathy), older men, and those with a history of genitourinary surgery are at increased risk for urinary retention. Post void residual (PVR) testing by catheterization or ultrasound can be helpful in patients who might have bladder outlet obstruction or urinary retention. Patients found to have suprapubic distention or fullness on physical examination should be further assessed by ultrasound or office in-and-out catheterization to determine if there is an elevated PVR.",
"   </p>",
"   <p>",
"    While parameters for interpreting the PVR results are neither standardized nor well tested, the results might lead one away from prescribing a bladder relaxant medication in patients with an increased PVR. In general, a PVR of less than 50 mL is considered adequate emptying, and a PVR greater than 200 mL may require referral for further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although measurements of urinary peak flow rate, as well as PVR, are included in all clinical trials of nocturia involving male subjects, there is no definitive evidence stating that results from these tests are necessary in directing choice of initial therapy. Men with low flow rates may report urinary intermittency or a long duration of voiding. Urine peak flow can be readily measured with a flow meter. Classically, a peak flow rate greater than or equal to 15",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    (for a voided volume of at least 150 mL) makes bladder outlet obstruction much less likely. A low flow rate may be due to either obstruction or detrusor underactivity. In population-based studies, urine flow rates were significantly slower among men with symptoms compared to those without symptoms; however, significant overlap exists [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/74\">",
"     74",
"    </a>",
"    ]. Additionally, it is not clear whether men with a lower flow rate treated with BPH medications have greater nocturia reductions than do men with higher flow rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal function, electrolytes, and serum glucose should be measured. A urinalysis should be performed in all patients, with urine culture if an infection is suspected. In older women, the interpretation of the urine culture must take into account the high prevalence of asymptomatic bacteriuria, which is not a cause of either incontinence or morbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=see_link\">",
"     \"Approach to the adult with asymptomatic bacteriuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urine cytology and cystoscopy are indicated only if hematuria or pelvic pain is present. Patients with undiagnosed prostate cancer are not more likely to have urinary symptoms. Nonetheless, PSA testing is reasonable in the evaluation of men with nocturia and other lower urinary symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    .) The Medical Treatment of Prostate Symptoms study showed that patients with lower PSA values (&lt;1.4) are less likely to benefit from 5-alpha-reductase inhibitors than those with higher PSA values [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ASSESSING TREATMENT OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used measure of nocturia treatment efficacy is a reduction in nocturia episodes. Cure, or the complete resolution of nocturia, is infrequently achieved, and probably unrealistic to expect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/32\">",
"     32",
"    </a>",
"    ]. It is important to recognize that most reports of treatment have shown only a small reduction in episodes of nocturia, ranging from 0 to 0.8 fewer episodes of nocturia versus placebo.",
"   </p>",
"   <p>",
"    An additional important target for therapy is the reduction in bother due to nocturia. Patient-based outcomes may be assessed using general satisfaction questions or urinary incontinence-specific quality of life measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INITIAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment includes adjustment of fluid intake, especially if fluid intake is excessive. Trials of fluid modification and caffeine reduction in women with incontinence have shown decreases in total 24-hour urinary frequency, but not specifically in nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/76\">",
"     76",
"    </a>",
"    ]. A randomized trial showed little effect on nocturia by variation in fluid intake [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/77\">",
"     77",
"    </a>",
"    ]. In addition to participant difficulty in complying with the recommended changes in fluid intake, reducing fluid by 50 percent resulted in a statistically insignificant increase in nocturia episodes (1.4 to 1.8), and increasing fluids by 25 or 50 percent had no effect on nocturia. Using fluid management as a part of an overall multicomponent management strategy may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimizing treatment for underlying conditions, such as diabetes or congestive heart failure, is important but has not directly been shown to reduce rates of nocturia. Patients needing twice daily diuretic medications may be helped by moving the nighttime diuretic dose to the mid-afternoon. Treatment of peripheral edema by compression stockings or afternoon elevation of the legs has been shown to be useful as part of a multi-component intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatments aimed at minimizing the bother from nocturia may be helpful, even if there is no effect on the nocturia itself. As an example, the use of a handheld urinal or a bedside commode may be helpful for patients bothered by trips to and from the bathroom at night.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     BEHAVIORAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral therapy, with an emphasis on pelvic floor muscle exercises and urge suppression strategies, has proven useful in women with nocturia and urge-predominant urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Pelvic floor muscle exercises (PFME, or Kegel exercises) strengthen the muscular components of the urethral closure mechanism using principles of strength training: small numbers of isometric repetitions at maximal exertion. The basic recommended regimen is three sets of 8 to 12 slow velocity contractions sustained for six to eight seconds each, performed three or four times a week and continued for at least 15 to 20 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?19/0/19456?source=see_link\">",
"     \"Patient information: Pelvic floor muscle exercises (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one randomized, controlled study in older women (n = 131) with urge or mixed incontinence and nocturia, a multi-component behavioral training program reduced nocturia by a median of 0.5 episodes per night. Behavioral training was significantly more effective than drug treatment (median reduction = 0.30 episodes) or placebo (no reduction) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/84\">",
"     84",
"    </a>",
"    ]. Studies examining the benefit in men of the addition of pelvic floor muscle exercises to alpha-blocker therapy have also shown similar beneficial reductions in nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications can be helpful for the treatment of nocturia associated with bladder overactivity, bladder outlet obstruction, and nocturnal polyuria. It should be noted that exclusion criteria for participation in some clinical trials may differ, and thereby influence results by eliminating patients less likely to respond to a specific medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Alpha-blocker agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostatic tissue contains alpha-1 and alpha-2 adrenergic receptors. Alpha-1 receptors are abundant in the prostate and base of the bladder, and sparse in the body of the bladder. Alpha-1-adrenergic antagonists target the dynamic component of bladder outlet obstruction and can reduce several BPH symptoms, including nocturia.",
"   </p>",
"   <p>",
"    However, reductions in nocturia with alpha blockers are modest (on average 0.2 to 0.4 fewer episodes compared to placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/86\">",
"     86",
"    </a>",
"    ]. Nocturia response to alpha blockers is significantly less than the response of other BPH-related symptoms. In one secondary data analysis, nocturia reduction of 50 percent or greater occurred in 39 percent of men treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    , compared to 22 percent of men treated with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/86\">",
"     86",
"    </a>",
"    ]. This relatively small effect in research trials with populations selected to have the best chance for benefit and carefully monitored for compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/75,87\">",
"     75,87",
"    </a>",
"    ] suggests that nocturia response in the general population will likely be even more minimal.",
"   </p>",
"   <p>",
"    If patients do experience a reduction in nocturia, the onset is rapid (within weeks to a month), compared to 5-alpha reductase inhibitors (see below). On the other hand, the least expensive alpha blockers (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    ) are often associated with dizziness and orthostatic hypotension, which may be of particular concern in patients with nocturia. These side effects can be minimized with gradual dose titration. The annual cost of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    is significantly higher (approximately fourfold) but these drugs require no dosage titration, and the incidence of dizziness and orthostasis is reduced (1 to 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of alpha-adrenergic receptors in the bladder outlet and neck provides a theoretic basis for the potential effectiveness of alpha-blockers in women with nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/90\">",
"     90",
"    </a>",
"    ]. Alpha-blocker therapy did not provide relief for nocturia in women in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     5-Alpha-reductase inhibitors (men only)",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-alpha reductase inhibitors decrease nocturia by reducing the size of the prostate gland. Treatment for four to six months is generally needed before prostate size is sufficiently reduced to improve symptoms. The type 2 form of 5-alpha-reductase catalyzes the conversion of testosterone to dihydrotestosterone in prostatic and other androgen-sensitive tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of long-term therapy with 5 alpha reductase inhibitors was evaluated in the Medical Therapy of Prostatic Symptoms (MTOPS) trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/75\">",
"     75",
"    </a>",
"    ]. Compared to previous studies that showed no benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    on lower urinary tract symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/87\">",
"     87",
"    </a>",
"    ] or nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/86\">",
"     86",
"    </a>",
"    ], the MTOPS study demonstrated benefit with finasteride on a combined end-point of reduction of BPH symptoms, need for intervention for urinary retention, and reduction of urinary symptoms. The MTOPS study also showed that combination therapy (finasteride plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    ) was superior to therapy with either single agent. However, the net benefit of combination therapy compared to placebo, with respect to nocturia, was small, with a difference of less than 0.2 fewer nightly episodes at one and four year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are small studies suggesting that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    to alpha-blocker therapy might be useful when treatment results from alpha-blocker therapy alone are unsatisfactory [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Bladder relaxant therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder relaxant medications allow for an increase in the bladder capacity and may reduce nocturia by both decreasing urge-associated voids and by increasing bladder capacity. Agents differ in efficacy, side effects, costs, and impact on co-morbid conditions that may improve or be exacerbated by the drug.",
"   </p>",
"   <p>",
"    Anticholinergics with antimuscarinic effects are frequently prescribed for nocturia. Several studies of these drugs have failed to demonstrate benefit for nocturia and remain unpublished [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/74\">",
"     74",
"    </a>",
"    ]. In studies that have shown benefit, the absolute benefit over placebo in terms of nocturia reduction has been small [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/84,94,95\">",
"     84,94,95",
"    </a>",
"    ]. These agents may be most useful for nocturia in combination with a second drug [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While many practitioners are comfortable prescribing bladder relaxants for women, there is concern that these agents may predispose men to urinary retention. Urodynamic studies have shown a small increase in the post-void residual; although statistically significant, this small change has not proven to be clinically meaningful [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/97,98\">",
"     97,98",
"    </a>",
"    ] and these drugs have been used successfully, with clinical monitoring, in older male patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/85,99\">",
"     85,99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Oxybutynin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"     Oxybutynin",
"    </a>",
"    is the most commonly used bladder muscle relaxant. It has direct antispasmodic effects and inhibits the action of acetylcholine on smooth muscle. Oxybutynin is available in immediate release (IR), extended release (ER), and transdermal formulations. In one randomized controlled study in 131 older women with urge or mixed (urge predominant) incontinence and nocturia, IR oxybutynin (started at 2.5 mg twice daily and titrated, as needed, up to a total daily dose of 15 mg) significantly reduced nocturia by 0.30 episodes per night, compared to control (no reduction) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/84\">",
"     84",
"    </a>",
"    ]. A similar effect size was seen in men with the addition of titrated oxybutynin XL added to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    0.4 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little is known about the comparative efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    IR versus ER for nocturia. The ER formulation has fewer side effects (particularly less dry mouth) but the IR theoretically might be preferred for nocturia if only nighttime usage is required. A single nighttime dosage of oxybutynin IR 2.5 or 5 mg might be useful for some patients with nocturia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Tolterodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a 12 week randomized study in patients with nocturia (mean 2.5 episodes nightly, n = 850),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    extended release 4 mg, compared with placebo, did not significantly reduce the total number of nocturnal micturitions but did reduce nocturnal urgency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/100\">",
"     100",
"    </a>",
"    ]. In another study, 12-week nighttime frequency was significantly reduced in men by approximately 0.3 episodes for those participants on combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    0.4 mg and tolterodine ER 4 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/101\">",
"     101",
"    </a>",
"    ]. Dry mouth is the most common side effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Solifenacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/33/39445?source=see_link\">",
"     Solifenacin",
"    </a>",
"    10 mg significantly decreased episodes of nocturia (-0.71 versus placebo -0.52) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/94\">",
"     94",
"    </a>",
"    ]. A pooled analysis of four randomized phase III trials found similar results for doses of 5 or 10 mg of solifenacin, although the study considered only patients with overactive bladder who did not have nocturnal polyuria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/102\">",
"     102",
"    </a>",
"    ]. Again, the net change in nocturia (-0.1 to -0.2) is small [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/94,102\">",
"     94,102",
"    </a>",
"    ], although patients do report subjective improvement from treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/103\">",
"     103",
"    </a>",
"    ]. The most common side effects were dry mouth, constipation and urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13656814\">",
"    <span class=\"h2\">",
"     Antidiuretic therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Desmopressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    (1-deamino-8-D-arginine vasopressin, ddAVP) therapy is used in Europe for treatment of adult nocturia under the age of 65. It is not approved for this indication in the United States, although it is frequently prescribed off-label. ddAVP is a neuropeptide that differs from endogenous vasopressin by a two-amino acid substitute of AVP which gives the compound potent antidiuretic effect but no vasopressor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of nocturnal polyuria has been linked to either inadequate nighttime levels of arginine vasopressin (AVP) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/106\">",
"     106",
"    </a>",
"    ] or inadequate diurnal variation of AVP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/107\">",
"     107",
"    </a>",
"    ]. ddAVP, taken two hours prior to bedtime, reduces nighttime urine production (with a compensatory, and necessary, increase in daytime urine production). The initial aim of therapy with ddAVP is to reduce nocturia and thereby provide adequate sleep; daytime diuresis should be addressed subsequently.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    is available as a nasal spray with dependable absorption. However, the oral tablet, with a shorter half-life, is the most commonly used formulation for treatment of nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/108\">",
"     108",
"    </a>",
"    ]. Oral ddAVP is available in 0.1, 0.2, and 0.4 dosages. Absorption from the GI tract is limited (about 5 percent) and therefore the oral form has about one-tenth to one-twentieth the potency of the nasal form. The initial oral dose for nocturia is 0.1 mg, though some suggest a 0.05 mg starting dosage. The tablet should not be taken with meals in order to maximize absorption, and should be started at the lowest possible dose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/109,110\">",
"     109,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum sodium levels should be monitored within three days of initiation of therapy and can be titrated to a higher dose if no hyponatremia is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/111\">",
"     111",
"    </a>",
"    ]. ddAVP, due to its prolonged duration of action, can result in free-water excess and hyponatremia. Severe hyponatremia has occurred even within the context of a clinical trial with enhanced, structured monitoring and lower-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/110\">",
"     110",
"    </a>",
"    ]. Unrecognized hyponatremia may result in seizures or be life threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/112\">",
"     112",
"    </a>",
"    ]. The frequency of reported hyponatremia with ddAVP ranges from 3 to 30 percent, with a pooled estimate of 7.6 percent (95% CI 3.7-15.1) from studies completed as of 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/113\">",
"     113",
"    </a>",
"    ]. Most trials of ddAVP exclude patients with urinary urgency, poorly controlled diabetes mellitus, cardiac disorders, and those taking diuretics. The risk of hyponatremia with ddAVP increases 10-fold in patients with cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older patients are at greater risk of developing hyponatremia with ddAVP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/111\">",
"     111",
"    </a>",
"    ], likely due to a prolonged high plasma level of ddAVP with increased age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/112\">",
"     112",
"    </a>",
"    ]. Additionally, older patients have a greater likelihood of taking other medications (such as diuretics, nonsteroidal anti-inflammatory drugs, antidepressants, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ) that can also depress sodium levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although nocturnal polyuria is a more common cause of nocturia in older adults, we recommend that patients over age 65 years not be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    . Older patients with baseline low normal sodium have a 75 percent incidence of hyponatremia with ddAVP therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/115\">",
"     115",
"    </a>",
"    ]. In addition, a pilot study of 16 male patients (mean age 76.3 years) treated with desmopressin for one to five days found increased calcium and decreased potassium excretion, with potential consequences of increased risk for osteoporosis, urolithiasis, and hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several randomized trials have found ddAVP to be effective in treating men with nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/110,117-119\">",
"     110,117-119",
"    </a>",
"    ]. In one open label [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/117\">",
"     117",
"    </a>",
"    ] and two randomized placebo controlled trials of patients who had already demonstrated nocturia response to ddAVP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/118,119\">",
"     118,119",
"    </a>",
"    ], ddAVP was shown to decrease nocturia and increase time until first awakening by nearly two hours. Among patients with nocturnal polyuria and no symptoms suggestive of overactive bladder, ddAVP (titrated from 0.1 mg up to 0.4 mg if nocturia persisted) resulted in an average 1.3 episode reduction in men (versus 0.5 reduction in placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/118\">",
"     118",
"    </a>",
"    ]. Among patients who tolerated the drug during dosage titration, 85 percent were able to tolerate the drug over the period of one year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/117\">",
"     117",
"    </a>",
"    ]. In another randomized trial of ddAVP versus placebo in older men, those randomly assigned to ddAVP were much more likely to have a two episode reduction in nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/110\">",
"     110",
"    </a>",
"    ]. Both groups had severe nocturia at baseline (mean five nightly episodes).",
"   </p>",
"   <p>",
"    An orally-disintegrating tablet formulation of ddAVP, not yet available in the US, has been studied in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/120\">",
"     120",
"    </a>",
"    ]. The minimal effective dose for men was 100 mcg (mean nocturia change -1.38 versus -0.84 for placebo) and 25 mcg for women (mean nocturia change -1.22 versus -0.88 for placebo). Hyponatremia was more prevalent at higher doses, in older individuals and in women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     OTHER TREATMENT STRATEGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Surgical therapy for BPH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostatectomy for BPH relieves many symptoms, but nocturia is the symptom that persists most frequently following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/122\">",
"     122",
"    </a>",
"    ]. Some have suggested that BPH is often mistakenly implicated as the cause of nocturia in men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106920308\">",
"    <span class=\"h2\">",
"     Posterior tibial nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior tibial nerve stimulation (PTNS) involves transcutaneous needle nerve stimulation near the ankle, approximating pudendal nerve stimulation. PTNS has been studied in a sham-controlled randomized trial, evaluating the number of nocturia episodes in 214 patients with overactive bladder (OAB) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/124\">",
"     124",
"    </a>",
"    ]. The number of nocturia episodes in the group assigned to weekly PTNS for 12 weeks decreased compared to sham control (a decrease of 0.7 versus 0.3 episodes from a baseline of 2.9 nightly episodes). Improvement in nocturia was sustained over a 12-month period (0.8 episodes less than baseline) when participants had additional treatment on an average of every two to three weeks. It is not known if these gains would be maintained without ongoing treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Medication for sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies that have focused on treatment of nocturia with the use of medications for sleep. One randomized study investigated melatonin as a potential treatment for nocturia associated with bladder outflow obstruction in older men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/126\">",
"     126",
"    </a>",
"    ]. Baseline frequency of nocturia was 3.1 episodes per night. Melatonin (-0.32 episodes per night change) showed a trend towards reduction in nocturia compared to placebo (-.03 and -0.05 episodes respectively) and significantly reduced reported bother.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Afternoon diuretic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small studies have evaluated the effectiveness of an afternoon diuretic dose on nocturia. In two randomized double-blinded studies, nocturia was reduced by approximately 0.5 episodes per night [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. One trial found greatest benefit in men with enlarged prostates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/66\">",
"     66",
"    </a>",
"    ], the other in men with nocturnal polyuria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/67\">",
"     67",
"    </a>",
"    ]. This strategy is likely to be useful in the proper population, but studies have incompletely identified which participants are likely to benefit from this approach. Combining antidiuretic therapy (at bedtime) with diuretic therapy (six hours prior to bedtime) increased the effect size of reduction of nocturia but was accompanied by hyponatremia in several cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As nocturia is a manifestation of various conditions (ie, overactive bladder, benign prostatic hyperplasia, congestive heart failure, poorly controlled diabetes, peripheral edema, obstructive sleep apnea), numerous treatments are potentially helpful. The Third International Consultation on Incontinence specifically recommended use of multicomponent interventions to treat lower urinary tract symptoms in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Single agent therapies available for nocturia are limited in their effectiveness, as they cannot address all of the relevant causes of nocturia. Conditions with multiple causes can be most effectively addressed by multicomponent interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. Data from a case series has shown a statistically significant mean reduction of 1.2 episodes of nocturia per night for male patients with nocturia (n = 55) using a multicomponent intervention individualized to the patient, which variably incorporated two of three medications (bladder relaxant, alpha-blocker",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sedative hypnotic), diabetes management, sleep hygiene, fluid management, and daytime compression stockings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/29/28122/abstract/40\">",
"     40",
"    </a>",
"    ]. Accompanying this change was a mean 2-point improvement on a 5-point scale assessing bother impact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nocturia is defined as any waking at night to void, although two or more awakenings are most often considered clinically significant. It may be more beneficial to try to reduce the bother caused by the nocturia than to target a specific reduction in nocturia episodes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Providers must be alert to reports of nocturia and inquire about nocturia if a patient has sleep difficulties. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nocturia may be caused by conditions or disorders that result in low bladder volume voids, nocturnal polyuria, or sleep disturbances. Age, benign prostatic hyperplasia, congestive heart failure, renal disease, sleep apnea, diabetes mellitus, and diabetes insipidus are some of the conditions associated with nocturia. Many patients have multiple etiologies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation for nocturia should focus on patterns of fluid intake, other urinary symptoms, and a comprehensive physical examination. Fall risk at night should be considered. A basic chemistry profile including serum glucose should be obtained. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A frequency-volume chart (ie, a voiding diary) may be helpful in determining the type of nocturia. Nocturnal polyuria is defined as the excretion of &ge;35 percent of the 24-hour urine output during the hours of sleep. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Frequency-volume chart'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial measures should include adjustments in timing of fluid intake and eliminating nighttime diuretic use if present. Pelvic floor exercises and a urinal or commode near the bed may be helpful. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Initial measures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Behavioral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Single agent therapies for nocturia have limited impact on the number of episodes. We suggest trials of alpha-blockers with or without 5-alpha reductase inhibitors in men with nocturia related to BPH (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) and trials of bladder muscle relaxants for patients with low volume voids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For younger patients (&le;65 years of age) who have bothersome nocturia despite treatment above (behavioral and other pharmacologic therapy) and who have normal baseline sodium levels, we suggest treatment with ddAVP (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These patients must be able to recognize and report subtle changes in fluid and weight status, and be willing to have sodium levels monitored closely. Use of ddAVP for nocturia treatment is off-label (non-FDA approved) in the United States. ddAVP has potentially severe side effects and should not be prescribed for most older adults (over the age of 65). (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Desmopressin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/1\">",
"      Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010; 21:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/2\">",
"      Tikkinen KA, Johnson TM 2nd, Tammela TL, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol 2010; 57:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/3\">",
"      Chen FY, Dai YT, Liu CK, et al. Perception of nocturia and medical consulting behavior among community-dwelling women. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/4\">",
"      A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia. J Urol 1993; 150:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/5\">",
"      DuBeau CE, Yalla SV, Resnick NM. Implications of the most bothersome prostatism symptom for clinical care and outcomes research. J Am Geriatr Soc 1995; 43:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/6\">",
"      Van Dijk MM, Wijkstra H, Debruyne FM, et al. The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int 2010; 105:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/7\">",
"      Middelkoop HA, Smilde-van den Doel DA, Neven AK, et al. Subjective sleep characteristics of 1,485 males and females aged 50-93: effects of sex and age, and factors related to self-evaluated quality of sleep. J Gerontol A Biol Sci Med Sci 1996; 51:M108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/8\">",
"      van der Vaart CH, Roovers JP, de Leeuw JR, Heintz AP. Association between urogenital symptoms and depression in community-dwelling women aged 20 to 70 years. Urology 2007; 69:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/9\">",
"      Asplund R, Henriksson S, Johansson S, Isacsson G. Nocturia and depression. BJU Int 2004; 93:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/10\">",
"      Fitzgerald MP, Litman HJ, Link CL, et al. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. J Urol 2007; 177:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/11\">",
"      Siniorakis E, Kotsanis A, Kanderakis S, et al. Nocturia in males with heart failure: prostatic edema and circadian neurohormonal rhythm. Int J Cardiol 2008; 123:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/12\">",
"      Kupelian V, Fitzgerald MP, Kaplan SA, et al. Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. J Urol 2011; 185:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/13\">",
"      Vaughan CP, Brown CJ, Goode PS, et al. The association of nocturia with incident falls in an elderly community-dwelling cohort. Int J Clin Pract 2010; 64:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/14\">",
"      Stewart RB, Moore MT, May FE, et al. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992; 40:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/15\">",
"      Temml C, Ponholzer A, Gutjahr G, et al. Nocturia is an age-independent risk factor for hip-fractures in men. Neurourol Urodyn 2009; 28:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/16\">",
"      Nakagawa H, Niu K, Hozawa A, et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol 2010; 184:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/17\">",
"      van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/18\">",
"      Weiss JP, Blaivas JG. Nocturia. Curr Urol Rep 2003; 4:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/19\">",
"      Tikkinen KA, Tammela TL, Huhtala H, Auvinen A. Is nocturia equally common among men and women? A population based study in Finland. J Urol 2006; 175:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/20\">",
"      Liew LC, Tiong HY, Wong ML, et al. A population study of nocturia in Singapore. BJU Int 2006; 97:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/21\">",
"      Lin TL, Ng SC, Chen YC, et al. What affects the occurrence of nocturia more: menopause or age? Maturitas 2005; 50:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/22\">",
"      Markland AD, Vaughan CP, Johnson TM 2nd, et al. Prevalence of nocturia in United States men: results from the National Health and Nutrition Examination Survey. J Urol 2011; 185:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/23\">",
"      Kupelian V, Link CL, Hall SA, McKinlay JB. Are racial/ethnic disparities in the prevalence of nocturia due to socioeconomic status? Results of the BACH survey. J Urol 2009; 181:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/24\">",
"      Burgio KL, Johnson TM 2nd, Goode PS, et al. Prevalence and correlates of nocturia in community-dwelling older adults. J Am Geriatr Soc 2010; 58:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/25\">",
"      H&auml;kkinen JT, Hakama M, Shiri R, et al. Incidence of nocturia in 50 to 80-year-old Finnish men. J Urol 2006; 176:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/26\">",
"      Viktrup L. The risk of lower urinary tract symptoms five years after the first delivery. Neurourol Urodyn 2002; 21:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/27\">",
"      Johnson TM 2nd, Sattin RW, Parmelee P, et al. Evaluating potentially modifiable risk factors for prevalent and incident nocturia in older adults. J Am Geriatr Soc 2005; 53:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/28\">",
"      Tikkinen KA, Auvinen A, Johnson TM 2nd, et al. A systematic evaluation of factors associated with nocturia--the population-based FINNO study. Am J Epidemiol 2009; 170:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/29\">",
"      van Doorn B, Kok ET, Blanker MH, et al. Mortality in older men with nocturia. A 15-year followup of the Krimpen study. J Urol 2012; 187:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/30\">",
"      Digesu GA, Khullar V, Panayi D, et al. Should we explain lower urinary tract symptoms to patients? Neurourol Urodyn 2008; 27:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/31\">",
"      Hillier P, Knapp MS, Cove-Smith R. Circadian variations in urine excretion in chronic renal failure. Q J Med 1980; 49:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/32\">",
"      Weiss JP, Wein AJ, van Kerrebroeck P, et al. Nocturia: new directions. Neurourol Urodyn 2011; 30:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/33\">",
"      Mock LL, Parmelee PA, Kutner N, et al. Content validation of symptom-specific nocturia quality-of-life instrument developed in men: issues expressed by women, as well as men. Urology 2008; 72:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/34\">",
"      Booth J, McMillan L. The impact of nocturia on older people - implications for nursing practice. Br J Nurs 2009; 18:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/35\">",
"      Michel MC, Oelke M, Goepel M, et al. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. Neurourol Urodyn 2007; 26:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/36\">",
"      Vaughan CP, Eisenstein R, Bliwise DL, et al. Self-rated sleep characteristics and bother from nocturia. Int J Clin Pract 2012; 66:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/37\">",
"      Weiss JP, Blaivas JG. Nocturia. J Urol 2000; 163:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/38\">",
"      Chang SC, Lin AT, Chen KK, Chang LS. Multifactorial nature of male nocturia. Urology 2006; 67:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/39\">",
"      Weiss JP, Blaivas JG, Jones M, et al. Age related pathogenesis of nocturia in patients with overactive bladder. J Urol 2007; 178:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/40\">",
"      Vaughan CP, Endeshaw Y, Nagamia Z, et al. A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results. BJU Int 2009; 104:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/41\">",
"      van Haarst EP, Heldeweg EA, Newling DW, Schlatmann TJ. The 24-h frequency-volume chart in adults reporting no voiding complaints: defining reference values and analysing variables. BJU Int 2004; 93:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/42\">",
"      Pfisterer MH, Griffiths DJ, Schaefer W, Resnick NM. The effect of age on lower urinary tract function: a study in women. J Am Geriatr Soc 2006; 54:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/43\">",
"      Weiss JP, Blaivas JG, Stember DS, Chaikin DC. Evaluation of the etiology of nocturia in men: the nocturia and nocturnal bladder capacity indices. Neurourol Urodyn 1999; 18:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/44\">",
"      Miller M. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc 2000; 48:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/45\">",
"      Kirkland JL, Lye M, Levy DW, Banerjee AK. Patterns of urine flow and electrolyte excretion in healthy elderly people. Br Med J (Clin Res Ed) 1983; 287:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/46\">",
"      George CP, Messerli FH, Genest J, et al. Diurnal variation of plasma vasopressin in man. J Clin Endocrinol Metab 1975; 41:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/47\">",
"      Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med 1991; 229:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/48\">",
"      Matthiesen TB, Rittig S, N&oslash;rgaard JP, et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 1996; 156:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/49\">",
"      Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord 1995; 10:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/50\">",
"      Hajduk IA, Strollo PJ Jr, Jasani RR, et al. Prevalence and predictors of nocturia in obstructive sleep apnea-hypopnea syndrome--a retrospective study. Sleep 2003; 26:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/51\">",
"      Romero E, Krakow B, Haynes P, Ulibarri V. Nocturia and snoring: predictive symptoms for obstructive sleep apnea. Sleep Breath 2010; 14:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/52\">",
"      Moriyama Y, Miwa K, Tanaka H, et al. Nocturia in men less than 50 years of age may be associated with obstructive sleep apnea syndrome. Urology 2008; 71:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/53\">",
"      Lowenstein L, Kenton K, Brubaker L, et al. The relationship between obstructive sleep apnea, nocturia, and daytime overactive bladder syndrome in women. Am J Obstet Gynecol 2008; 198:598.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/54\">",
"      Endeshaw YW, Johnson TM, Kutner MH, et al. Sleep-disordered breathing and nocturia in older adults. J Am Geriatr Soc 2004; 52:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/55\">",
"      Pressman MR, Figueroa WG, Kendrick-Mohamed J, et al. Nocturia. A rarely recognized symptom of sleep apnea and other occult sleep disorders. Arch Intern Med 1996; 156:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/56\">",
"      Fitzgerald MP, Mulligan M, Parthasarathy S. Nocturic frequency is related to severity of obstructive sleep apnea, improves with continuous positive airways treatment. Am J Obstet Gynecol 2006; 194:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/57\">",
"      Umlauf MG, Chasens ER, Greevy RA, et al. Obstructive sleep apnea, nocturia and polyuria in older adults. Sleep 2004; 27:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/58\">",
"      Krieger J, Laks L, Wilcox I, et al. Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure. Clin Sci (Lond) 1989; 77:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/59\">",
"      H&auml;kkinen JT, Shiri R, Koskim&auml;ki J, et al. Depressive symptoms increase the incidence of nocturia: Tampere Aging Male Urologic Study (TAMUS). J Urol 2008; 179:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/60\">",
"      Kupelian V, Wei JT, O'Leary MP, et al. Nocturia and quality of life: results from the Boston area community health survey. Eur Urol 2012; 61:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/61\">",
"      Laven BA, Orsini N, Andersson SO, et al. Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 2008; 179:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/62\">",
"      Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/63\">",
"      Abrams P, Klevmark B. Frequency volume charts: an indispensable part of lower urinary tract assessment. Scand J Urol Nephrol Suppl 1996; 179:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/64\">",
"      Matzkin H, Greenstein A, Prager-Geller T, et al. Do reported micturition symptoms on the American Urological Association Questionnaire correlate with 24-hour home uroflowmetry recordings? J Urol 1996; 155:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/65\">",
"      Blanker MH, Bohnen AM, Groeneveld FP, et al. Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. J Urol 2000; 164:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/66\">",
"      Pedersen PA, Johansen PB. Prophylactic treatment of adult nocturia with bumetanide. Br J Urol 1988; 62:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/67\">",
"      Reynard JM, Cannon A, Yang Q, Abrams P. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 1998; 81:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/68\">",
"      Ouslander JG. Management of overactive bladder. N Engl J Med 2004; 350:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/69\">",
"      Edwards KR, O'Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002; 50:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/70\">",
"      Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/71\">",
"      Weiss JP. Nocturia: \"do the math\". J Urol 2006; 175:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/72\">",
"      Rembratt A, Norgaard JP, Andersson KE. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int 2003; 91:45.",
"     </a>",
"    </li>",
"    <li>",
"     Fantl JA, et al.. Urinary incontinence in adults: Acute and chronic management. Clinical Practice Guideline No. 2, 1996 Update. AHCPR Publication NO. 96-0682, Agency for Health Care Policy and Research; Department of Health and Human Services, Rockville, MD 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/74\">",
"      Diokno AC, Brown MB, Goldstein NG, Herzog AR. Urinary flow rates and voiding pressures in elderly men living in a community. J Urol 1994; 151:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/75\">",
"      McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/76\">",
"      Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol 2005; 174:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/77\">",
"      Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int 2008; 102:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/78\">",
"      Soda T, Masui K, Okuno H, et al. Efficacy of nondrug lifestyle measures for the treatment of nocturia. J Urol 2010; 184:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/79\">",
"      Johnson TM, Endeshaw Y, Nagamia Z, et al. A multicomponent intervention for nocturia in men. J Am Geriatr Soc 2005; 53:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/80\">",
"      Burgio KL. Current perspectives on management of urgency using bladder and behavioral training. J Am Acad Nurse Pract 2004; 16:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/81\">",
"      Teunissen TA, de Jonge A, van Weel C, Lagro-Janssen AL. Treating urinary incontinence in the elderly--conservative therapies that work: a systematic review. J Fam Pract 2004; 53:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/82\">",
"      Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 2002; 288:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/83\">",
"      Burgio KL, Goode PS. Behavioral interventions for incontinence in ambulatory geriatric patients. Am J Med Sci 1997; 314:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/84\">",
"      Johnson TM 2nd, Burgio KL, Redden DT, et al. Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 2005; 53:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/85\">",
"      Burgio KL, Goode PS, Johnson TM, et al. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. J Am Geriatr Soc 2011; 59:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/86\">",
"      Johnson TM 2nd, Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003; 170:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/87\">",
"      Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/88\">",
"      de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998; 33:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/89\">",
"      Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/90\">",
"      Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology 2003; 62:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/91\">",
"      Lepor H, Theune C. Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. J Urol 1995; 154:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/92\">",
"      Johnson TM 2nd, Burrows PK, Kusek JW, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 2007; 178:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/93\">",
"      Cho MC, Ku JH, Paick JS. Alpha-blocker plus diuretic combination therapy as second-line treatment for nocturia in men with LUTS: a pilot study. Urology 2009; 73:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/94\">",
"      Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/95\">",
"      Yokoyama O, Yamaguchi O, Kakizaki H, et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J Urol 2011; 186:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/96\">",
"      Ruggieri MR Sr, Braverman AS, Pontari MA. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 2005; 174:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/97\">",
"      Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/98\">",
"      Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/99\">",
"      Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/100\">",
"      Rackley R, Weiss JP, Rovner ES, et al. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006; 67:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/101\">",
"      Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/102\">",
"      Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006; 60:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/103\">",
"      Garely AD, Lucente V, Vapnek J, Smith N. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Ann Pharmacother 2007; 41:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/104\">",
"      Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006; 4:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/105\">",
"      Cvetkovi�� RS, Plosker GL. Desmopressin: in adults with nocturia. Drugs 2005; 65:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/106\">",
"      Asplund R, Aberg H. Diurnal rhythm of antidiuretic hormone in elderly subjects with nocturia. Med Sci Res 1991; 19:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/107\">",
"      Moon DG, Jin MH, Lee JG, et al. Antidiuretic hormone in elderly male patients with severe nocturia: a circadian study. BJU Int 2004; 94:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/108\">",
"      Rembratt A, Graugaard-Jensen C, Senderovitz T, et al. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol 2004; 60:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/109\">",
"      Johnson TM, Burridge A, Issa MM, et al. The relationship between the action of arginine vasopressin and responsiveness to oral desmopressin in older men: a pilot study. J Am Geriatr Soc 2007; 55:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/110\">",
"      Wang CJ, Lin YN, Huang SW, Chang CH. Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. J Urol 2011; 185:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/111\">",
"      Rembratt A, Norgaard JP, Andersson KE. Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns. BJU Int 2003; 91:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/112\">",
"      Hvistendahl GM, Riis A, N&oslash;rgaard JP, Djurhuus JC. The pharmacokinetics of 400 microg of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect. BJU Int 2005; 95:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/113\">",
"      Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol Urodyn 2004; 23:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/114\">",
"      Ljung R. Use of desmopressin and concomitant use of potentially interacting drugs in elderly patients in Sweden. Eur J Clin Pharmacol 2008; 64:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/115\">",
"      Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006; 25:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/116\">",
"      Chang YL, Lin AT, Chen KK. Short-term effects of desmopressin on water and electrolyte excretion in adults with nocturnal polyuria. J Urol 2007; 177:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/117\">",
"      Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004; 172:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/118\">",
"      Mattiasson A, Abrams P, Van Kerrebroeck P, et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002; 89:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/119\">",
"      Lose G, Lalos O, Freeman RM, et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003; 189:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/120\">",
"      Weiss JP, Zinner NR, Klein BM, N&oslash;rgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn 2012; 31:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/121\">",
"      Juul KV, Klein BM, Sandstr&ouml;m R, et al. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol 2011; 300:F1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/122\">",
"      Meyhoff HH, Nordling J. Long term results of transurethral and transvesical prostatectomy. A randomized study. Scand J Urol Nephrol 1986; 20:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/123\">",
"      Homma Y. Classification of nocturia in the adult and elderly patient: a review of clinical criteria and selected literature. BJU Int 2005; 96 Suppl 1:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/124\">",
"      Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010; 183:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/125\">",
"      MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol 2010; 183:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/126\">",
"      Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol 2004; 171:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/127\">",
"      Fu FG, Lavery HJ, Wu DL. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn 2011; 30:312.",
"     </a>",
"    </li>",
"    <li>",
"     Fonda D, DuBeau CE, Hatari MD, et al. Incontinence in the frail elderly. In: Incontinence, Abrams P, Cardozo L, Khoury S, et al (Eds), Health Publications Ltd, Paris 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/129\">",
"      Tinetti ME, Inouye SK, Gill TM, Doucette JT. Shared risk factors for falls, incontinence, and functional dependence. Unifying the approach to geriatric syndromes. JAMA 1995; 273:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/29/28122/abstract/130\">",
"      Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48:370.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6877 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28122=[""].join("\n");
var outline_f27_29_28122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Low volume bladder voids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Increased nighttime urinary volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nocturnal polyuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Polyuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fluid intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Urinary tract symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Frequency-volume chart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ASSESSING TREATMENT OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INITIAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      BEHAVIORAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Alpha-blocker agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      5-Alpha-reductase inhibitors (men only)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Bladder relaxant therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Oxybutynin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Tolterodine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Solifenacin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13656814\">",
"      Antidiuretic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Desmopressin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      OTHER TREATMENT STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Surgical therapy for BPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106920308\">",
"      Posterior tibial nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Medication for sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Afternoon diuretic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6877\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6877|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?33/7/33906\" title=\"form 1\">",
"      Intake and void volume record",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6877|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/8/42124\" title=\"table 1\">",
"      Factors causing nocturia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/18/42284\" title=\"table 2\">",
"      Diag considerations nocturia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34104?source=related_link\">",
"      Epidemiology and pathogenesis of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/0/19456?source=related_link\">",
"      Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_29_28123="Postexposure rabies PI";
var content_f27_29_28123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rabies postexposure guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type of animal",
"      </td>",
"      <td class=\"subtitle1\">",
"       Observation or testing of animal",
"      </td>",
"      <td class=\"subtitle1\">",
"       Postexposure prophylaxis recommendations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Dogs, cats, and ferrets",
"      </td>",
"      <td>",
"       Rabid or suspicion of rabies",
"      </td>",
"      <td colspan=\"1\">",
"       Immediately begin prophylaxis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       Healthy and available for 10 days' observation",
"      </td>",
"      <td colspan=\"1\">",
"       <p>",
"        Do not begin prophylaxis unless:",
"       </p>",
"       <p>",
"        Bite or non-bite exposure is to the head and neck OR",
"       </p>",
"       <p>",
"        Animal develops signs of rabies",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Unavailable for observation or testing",
"      </td>",
"      <td colspan=\"1\">",
"       Consult public health officials; consider immediate vaccination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Raccoons, foxes, skunks, coyotes and other carnivores; bats",
"      </td>",
"      <td>",
"       Consider rabid unless available for testing and proven not to be infected",
"      </td>",
"      <td colspan=\"1\">",
"       Consider immediate vaccination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Large rodents, small rodents, livestock, lagomorphs and other mammals",
"      </td>",
"      <td>",
"       Consider on an individual basis",
"      </td>",
"      <td colspan=\"1\">",
"       Consult public health officials",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Non-mammals",
"      </td>",
"      <td>",
"       Do not harbor rabies",
"      </td>",
"      <td>",
"       Prophylaxis",
"       <strong>",
"        never",
"       </strong>",
"       required",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28123=[""].join("\n");
var outline_f27_29_28123=null;
var title_f27_29_28124="Recognizing M-protein in serum and urine";
var content_f27_29_28124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recognizing a monoclonal protein (M-protein) in the serum and urine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Studies on serum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total serum protein",
"       </td>",
"       <td>",
"        An elevated total serum protein level does not distinguish among the type of protein that is elevated (ie, albumin, immunoglobulin, other) and cannot differentiate a monoclonal from a polyclonal increase.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum protein electrophoresis (SPEP)",
"       </td>",
"       <td>",
"        SPEP uses electrophoresis to separate serum proteins and allows for the detection and quantification of a monoclonal protein (M-protein) in the blood. Once detected, the monoclonality must be confirmed using serum immunofixation, serum immunoelectrophoresis, or serum immunosubtraction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum immunofixation",
"       </td>",
"       <td>",
"        This test uses antibodies directed against heavy chain and light chain components to differentiate a monoclonal from a polyclonal increase in immunoglobulins and to determine the type of immunoglobulin involved (eg, IgG kappa). This test does not quantify the M-protein.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum free light chain (FLC) assay",
"       </td>",
"       <td>",
"        The serum FLC assay is an antibody-based system that can detect low concentrations of monoclonal free light chains (ie, kappa or lambda) in the serum. This assay is more sensitive for the detection of light chains than urine immunofixation; however, results may be affected by the presence of renal failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quantitation of immunoglobulins",
"       </td>",
"       <td>",
"        This technique can detect hypogammaglobulinemia and hypergammaglobulinemia, but does not allow an assessment of monoclonality. Increased levels can be due to polyclonal or monoclonal elevations; clonality needs to be established using SPEP and immunofixation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Studies on urine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dipstick testing",
"       </td>",
"       <td>",
"        Although dipsticks are used in many laboratories to screen for the presence of protein in the urine, these tests are unable to detect Bence Jones protein (free kappa or lambda light chains).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine protein electrophoresis (UPEP)",
"       </td>",
"       <td>",
"        The UPEP uses electrophoresis to separate urine proteins. A 24-hour urine collection is necessary to determine the quantity of M-protein.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine immunofixation",
"       </td>",
"       <td>",
"        Urine immunofixation uses antibodies directed against the light chain components to differentiate a monoclonal from a polyclonal increase in immunoglobulins and to determine the type of light chain involved. Urine immunofixation is more sensitive than UPEP, but cannot estimate the size of the monoclonal protein.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28124=[""].join("\n");
var outline_f27_29_28124=null;
var title_f27_29_28125="Contents: Oncology calculators";
var content_f27_29_28125=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Oncology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Oncology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/31/4593\">",
"           Calculator: Body Surface Area (Du Bois Method)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/27/4529\">",
"           Calculator: Body Surface Area (Mosteller, square root method)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-CBEC274595-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_29_28125=[""].join("\n");
var outline_f27_29_28125=null;
var title_f27_29_28126="Adult proximal fibular fracture";
var content_f27_29_28126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal fibula fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This set of anteroposterior and lateral radiographs of the knee and lower leg shows a transverse fracture of the proximal fibula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl B Fields, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28126=[""].join("\n");
var outline_f27_29_28126=null;
var title_f27_29_28127="Buccal hemangioma";
var content_f27_29_28127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vascular hemangioma of the buccal mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martha Ann Keels, DDS, PhD, Duke Pediatric Dentistry.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_29_28127=[""].join("\n");
var outline_f27_29_28127=null;
